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                                                                 ABSTRACT 
 
           Endothelin-1 (ET-1) has been implicated in allergic type of respiratory inflammatory 
diseases in various species of animals including horses. This peptide elicits its actions by acting 
through endothelin-A (ET-A) and endothelin-B (ET-B) receptor sub-types. In this project, we 
have hypothesized that endothelin receptors (both ET-A and ET-B) are altered in terms of 
affinity and expression, in the lungs of summer pasture-associated obstructive pulmonary disease 
(SPAOPD)-affected horses. Objective of this dissertation was to determine the alterations in the 
affinity and expression of endothelin receptors in the lungs of healthy and SPAOPD-affected 
horses. To pursue our hypothesis, we have employed pharmacological, immunohistochemical 
and molecular studies. Totally 33 horses were used in this study. All the horses were examined 
and grouped in to 16 healthy and 17 SPAOPD-affected, based on clinical evaluation, clinical 
scoring, pulmonary function testing and broncho-alveolar lavage fluid (BALF) analysis. Horses 
were then euthanatized, and tissue specimens were immediately collected from all lung lobes. In 
pharmacological studies, cumulative concentration response curves and pA2 values were 
determined and compared in both groups of horses. The pA2 value of ET-B receptors was 
significantly greater in the SPAOPD-affected horses when compared with healthy horses. In 
immunohistochemical studies, expression of these receptors was determined in the bronchial 
smooth muscles and epithelium of both groups of horses. The percentage of immunostaining was 
significantly greater in the smooth muscles of SPAOPD-affected horses when compared with 
healthy horses. In molecular studies, by employing RT-PCR, western blotting and realtime PCR, 
expression of these receptors has been determined and compared. The molecular expression of 
ET-B receptors was siginifcantly greater in the peripheral lungs of SPAOPD-affected horses 
when compared with healthy horses. Specific antagonists, primers and polyclonal primary 
 xv
antibodies of ET-A or ET-B receptors were used for these three studies.  On the whole, it can be 
concluded that ET-B receptors show a clear tendency of up-regulation in the lungs of SPAOPD-
affected horses. These findings help us in the better understanding of the pathogenesis of this 




























































CHAPTER 1. REVIEW OF THE LITERATURE ON SUMMER-PASTURE-
























1.1. Introduction to Recurrent Airway Obstruction and Summer-Pasture-Associated 
Obstructive Pulmonary Disease 
 
           Recurrent airway obstruction or (RAO), also known as heaves, is a common 
inflammatory/allergic obstructive airway condition that affects many horses worldwide. This 
disease has two forms. The first and most widely reported form of RAO is chronic obstructive 
pulmonary disease (COPD), which is most prevalent in the northern hemisphere where horses 
are stabled for large portions of their lives and are fed hay. The other form is known as summer-
pasture-associated obstructive pulmonary disease (or SPAOPD), which frequently occurs in the 
southeastern United States, Britain and California in horses that are kept on pasture when the 
weather is warm and humid. Evidence suggests that the clinical signs and pathology of these two 
forms of RAO are the same but with different causative factors. 
            The first description of SPAOPD was reported by Dr. Ralph E. Beadle in 1983. In book 
chapter, he described this disease as “a syndrome with signs similar to the equine chronic 
obstructive pulmonary disease or heaves, a condition observed in stabled horses exposed to 
moldy hay or bedding and dust, but occurring in horses grazing pasture land in the summer in the 
southeastern region of USA, especially Florida, Georgia, Louisiana and Mississippi” (Beadle, 
1983). In 1993, Seahorn and Beadle reported a retrospective study of 21 cases of SPAOPD-
affected horses. In this study, they reviewed the medical records of case accessions from 1983 to 
1991 to identify the horses with COPD and a history of worsening clinical symptoms after 
exposure to pasture (i.e. SPAOPD). They concluded that SPAOPD is a disease of adult horses 
(mean age, 13.6 ± 3.6 years) that are on pasture most of the time in summer. They also reported 
the existence of significant breed and reproductive status differences in the occurrence of this 
disease. However, they concluded that those differences were confounded and clinically 
unimportant (Seahorn and Beadle 1993). Occurrence of this condition in the United Kingdom 
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was first reported by McGorum in 1990, and later was supported by Dixon and co-workers in 
1995 and Mair in 1996 (Dixon et al. 1995, Mair 1996). Nevertheless, the condition in the UK 
differs from that of US in that exacerbation of the disease occurs during hot dry weather 
following exposure to dust that originate from adjacent fields when crops are harvested or straw 
is burned (McGorum and Dixon 1999). 
             The etiology of SPAOPD is unclear; however, involvement of pollen and fungal spores 
is suggested. Previous studies have established the importance of fungi in the causation of airway 
allergic diseases in animals and humans. In 1994, Seahorn and Beadle have conducted a study to 
identify the predominant fungi present in the nasal passages of horses clinically affected with 
SPAOPD (Seahorn and Beadle 1994). They demonstrated that the most frequently isolated fungi 
from the control or unaffected horses in the pasture environment were Cladosporium spp., 
Acremonium spp., Choanephora spp., Curvularia sp., Fusarium sp., and Alternaria spp. The 
most frequently isolated fungi from eight SPAOPD-affected horses which did not show any 
clinical signs and seven SPAOPD-affected horses that did show clinical signs were 
Cladosporium spp., Curvularia spp., Fusarium spp., and Alternaria spp. They concluded that the 
fungal species Choanephora sp., Curvularia spp., and Fusarium spp. might play a vital role in 
the etiology of SPAOPD. In addition, they reported that Micropolyspora feani and Aspergillus 
fumigatus, which are the most important causes for COPD, were not identified in any of the 
SPAOPD-affected horses. This suggests that even though COPD and SPAOPD share many 
pathological features, they differ regarding the causative factors. On the whole, numerous future 




1.2 Clinical Features of SPAOPD 
            The clinical symptoms of equine SPAOPD are similar to those of equine COPD and 
human asthma, which include airway hyperresponsiveness and airway obstruction. The 
susceptible horses manifest the symptoms when they are exposed to pasture in the late summer 
to early fall.  
           A detailed description of the clinical symptoms exhibited by SPAOPD affected horses 
was reported by Seahorn and Beadle in 1993. In this survey, they reported the observations made 
by horse owners and veterinarians regarding the clinical symptoms of SPAOPD-affected horses 
(Seahorn and Beadle 1993). In this report they included a total of 21 SPAOPD-affected horses.  
All affected horses were typically tachypneic and had signs of expiratory dyspnea, but they were 
not febrile, anorectic or depressed. Auscultation of the thorax often revealed inspiratory and 
expiratory crackles and wheezes. Vibration from the mucus within the trachea was common. The 
hemogram was characterized by normal WBC count, but the neutrophil count was slightly 
increased, which may have been associated with stress of transportation and hospitalization. 
Aspirates collected by transtracheal wash fluids were characterized by the presence of 
nondegenerate neutrophils and proteinaceous swirls of mucus (i.e Curschmann’s spirals). 
Curschmann’s spirals are the casts of inspissated mucus plugs originating from the smaller 
airways which have been recognized in horses with chronic lung diseases. Bacteria were 
infrequently found in the transtracheal wash and were rarely grown on culture, suggesting that 
bacteria were unimportant in the etiopathogenesis of the disease.   
              Similar findings were reported by Costa and co-workers in 2000. In addition to the 
aforementioned features, these authors noticed the presence of small strands of yellow to white 
mucus scattered through the trachea (Costa et al. 2000). The bronchoalveolar lavage fluid 
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(BALF) of SPAOPD-affected horses contains a significantly greater percentage of 
nondegenerate neutrophils, compared with healthy horses.  
           Over-inflation of the lungs was a common feature of SPAOPD horses. However, true 
emphysema was not frequently observed. Over-inflation of the lungs was due to the air trapped 
in the post-obstructive areas. Cytologic evaluation of the BALF from SPAOPD-affected horses 
revealed the predominance of neutrophils, followed by lymphocytes, macrophages and mast 
cells. The SPAOPD-affected horses had significantly lower percentages of lymphocytes, 
macrophages, and mast cells in BALF, compared with normal horses. Results of bacteriological 
culture were negative in all horses. The lungs of SPAOPD-affected horses failed to collapse 
when the thoracic cavity was opened. Lungs retained the impressions made by the ribs. The 
lungs were orange-pink and had spongy texture. Many had a white, foamy substance on the 
visceral and parietal pleural surfaces. In clinically healthy horses, the lungs collapsed after the 
thoracic cavity was opened. In these horses, lungs had normal texture, pale-pink appearance and 
minimal or no foam on the external and cut surfaces.  
              These authors also reported that histologically the most consistent finding was the 
presence of extensive amounts of basophilic stained mucus within the small airways. 
Peribronchiolar inflammation was variable and characterized by the predominance of neutrophils 
and lymphocytes. Peribronchiolar smooth muscle hypertrophy was not a consistent feature. 
Presence of peribronchial eosinophils was rarely noticed. However, the authors did not rule out 
the possibility of the presence of eosinophils in the BALF of SPAOPD-affected horses at some 
point during the disease course. They also suggested the likelihood of the involvement of 
multiple pathogenic mechanisms in the development of this disease, which could result in 
variations in the proportion of the type of inflammatory cells. They also concluded that, as far as 
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the pathological changes are concerned, there were no qualitative or quantitative differences 
among the lobes. Finally, they stated that the clinical, cytological and histological features 
observed in SPAOPD were quite similar to those of equine COPD. 
1.3. Innervation of Equine Airways 
             Similar to most of the other species, equine airways are also innervated by cholinergic, 
adrenergic and non-adrenergic-non-cholinergic inhibitory (iNANC) and excitatory nervous 
systems (eNANC) (Matera et al. 2002). The airway innervation plays an important role in the 
regulation of the airway smooth muscle tone, airway secretion, blood flow and vascular 
permeability. Furthermore, airway innervation also plays a vital role in the modulation of 
inflammatory mechanisms involved in pulmonary disease.  
1.3.1 Cholinergic Nervous System – The cholinergic nervous system innervates the entire 
tracheobronchial tree. The preganglionic cholinergic nerves originate in the brain stem, pass via 
the vagus nerve and relay in the ganglia located in the alveolar walls. The postganglionic nerves 
originating from these ganglia innervate the airway smooth muscles and submucosal glands. The 
ganglionic neurotransmission is mediated by acetylcholine via nicotinic receptors, whereas the 
airway smooth muscle contraction is mediated by acetylcholine via muscarinic receptors.  
            The in vivo administration of atropine to RAO-affected horses results in the dilatation of 
all the levels of the tracheobronchial tree, suggesting that cholinergic innervation is present in the 
trachea and larger and smaller bronchi (Matera et al. 2002). This also indicates that cholinergic 
bronchoconstriction in horses is mediated by muscarinic receptors. At least 5 subtypes of 
muscarinic receptors have been cloned and characterized (i.e. M1 to M5), while four subtypes are 
recognized pharmacologically (i.e. M1 to M4). Each of these subtypes has a distinct role in the 
maintainence of normal airway physiology.  
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             The M1 and M2 receptors are localized on parasympathetic ganglia and postganglionic 
nerves, respectively. M1 receptors facilitate the ganglionic neurotransmission mediated by the 
nicotinic receptors. They also play an important role in the reflex pathways in various species. In 
humans and guinea pigs, M2  receptors are located in the prejunctional regions of the 
postganglionic nerves and play a vital role in the auto-regulation of acetylcholine secretion in the 
ganglia. When acetylcholine acts on these receptors, its release is inhibited in the ganglia. 
However, recently it has been suggested that the auto-receptor subtype in guinea pigs are of the 
M4 subtype rather than M2 (Matera et al. 2002). In equine airways, muscarinic auto-receptors 
also exist; however, it is still unknown which sub-type is involved in the auto-regulation of 
acetylcholine secretion. Wang and co-workers demonstrated that the muscarinic auto-receptors 
in equine airways do not belong to M1, M2 or M3, but may belong to a novel sub-type (Wang et 
al. 1995). Zhang and co-workers have demonstrated that equine RAO is not associated with 
dysfunction of muscarinic auto-receptors as observed in human asthma (Zhang et al. 1999). This 
is because human asthma is characterized by an increase in the number of eosinophils in the 
airways and these eosinophils synthesize inflammatory proteins such as major basic protein in 
the lungs. These proteins induce the release of excessive amounts of acetylcholine when they act 
upon muscarinic auto-receptors. In equine RAO, there is no increase in the levels of eosinophils 
in airways. Instead, a significant increase in the levels of neutrophils is noticed in this disease 
and therefore no dysfunction of muscarinic auto-receptors is observed. However, these authors 
have not ruled out the possibility of the influence of various inflammatory mediators in the 
regulation of acetylcholine release from post-ganglionic nerves.  
              In many species, the main function of the M3 receptor sub-type in airways is smooth 
muscle contraction. In addition, these receptors are also located in the airway epithelium, 
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submucosal glands and pulmonary vascular endothelium where they yield cholinergic-mediated 
vasodilatation. In vitro studies have demonstrated that the cholinergic-mediated airway smooth 
muscle contraction in equine species is mediated by the M3 receptor sub-type (Wang et al. 1995). 
In horses, these receptor sub-types are located in the trachea and small airways.  
          In airway allergic diseases of horses as well as in the other species, cholinergic-mediated 
mechanisms play a vital role in the etiology of the hyperresponsiveness. This is the reason why 
anti-cholinergic drugs are as effective as beta agonists in the treatment of these diseases 
(Robinson et al. 1993).  
1.3.2 Adrenergic Nervous System – Little information is available regarding the sympathetic 
innervation in equine airways. Sonea and co-workers have demonstrated that the sympathetic 
nerves are found more in the larger than in smaller airways (Sonea et al. 1993). They also 
reported the presence of numerous immunoreactive adrenergic nerves in pulmonary and 
bronchial vessels.   
           Adrenergic-mediated actions are elicited by two receptor subtypes i.e. α and β. Αt least 
three subtypes of β receptors exist:  β1, β2 and β3. Among these three subtypes, β2 receptors are 
widely distributed in the lungs and are located in various types of cells in the lungs. The 
β2 agonists decrease airway smooth muscular tone by causing relaxation of the smooth muscles; 
this is mediated by the accumulation of intracellular c-AMP which in turn reduces the 
intracellular concentration of calcium by activating protein kinase-A. In equine species, it has 
been shown that even though both β1 and β2 adrenergic receptors are present and activated in 
RAO, airway dilatation is primarily mediated by β2 receptor sub-types (Scott et al 1991). The 
α receptors are further classified into α1 and α2. In canine and guinea pig airways, α1 receptors 
have been demonstrated in the airway smooth muscles and they mediate contraction. 
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 However, in ponies affected with RAO, the role of these receptors in causing airway smooth 
muscle contraction is negligible (Scott et al. 1988). The α2 receptors are inhibitory receptors 
unlike that of α1 receptors. In addition, these receptors have been shown to be located on the 
cholinergic nerves, which when activated, could be responsible for the decrease of acetylcholine 
release. In other words, they act as auto-regulatory receptors (Zhang et al. 1999). 
              Besides its well known direct effects, the sympathetic nervous system also elicits 
indirect effects on the airways by interacting with the cholinergic nervous system. For example, 
exogenously applied adrenaline causes the inhibition of ganglionic neurotransmission in cat and 
ferret isolated airways by acting through α and β adrenergic receptors (Johnson 1998). In human 
airways, β2 agonists decrease the contractions elicited by cholinergic nerves and tachykinins 
(Johnson 1998). In equine airways, the presence of α2 and β2 receptors on the cholinergic nerves 
has been demonstrated with the former being predominant (Zhang et al. 1995). These receptors 
have been shown to have a modulatory effect on the cholinergic neurotransmission in the equine 
tracheobronchial tree. Particularly, α2 receptor subtypes have an inhibitory effect on the release 
of acetylcholine from the cholinergic nerves in equine large and small airways. The β2 receptors 
are distributed in the cholinergic nerves throughout the equine airways. In contrast to other 
species, activation of β2 receptors present on the cholinergic nerves of equine airways leads to an 
increased release of acetylcholine from the postganglionic cholinergic nerves. Similar behavior 
of β2 receptors has been observed in guinea pig trachea (Belvisi et al. 1996).  Zhang and co-
workers have suggested that this idiosyncratic effect of β2 receptors in equine airways could be 
due to the paradoxical effect of c-AMP, which might cause augmented release of acetylcholine 
from the cholinergic nerves (Zhang et al. 1996).  
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1.3.3 Non-Adrenergic-Non-Cholinergic (NANC) Nervous System – The non-adrenergic-non-
cholinergic (NANC) nervous system is comprised of the neurally mediated responses which are 
not blocked by the antagonists of either the adrenergic or cholinergic nervous system or both. 
The NANC has two components: excitatory NANC (e-NANC) and inhibitory NANC (i-NANC). 
In the airways, it has been shown pharmacologically and histologically that e-NANC nerve fibers 
form diffuse networks in the smooth muscles, submucosal glands and blood vessels (Barnes et al, 
1990). The neuropeptides such as tachykinins act as the transmitters of the NANC system. These 
peptides are synthesized in the ganglionic neural cell bodies and are transported to the peripheral 
nerve endings and are released into the peripheral tissues. These neuropeptides are contained 
mainly in the afferent chemosenstive C-fibers. Tachykinins mediate a multitude of functions in 
the body such as cholinergic neurotransmission, mucus secretion, smooth muscle contraction, 
inflammatory cell activation and plasma protein leakage from the tracheobronchial micro-
circulation etc.  
           It is well established that substance P (SP) is the neurotransmitter of the e-NANC. 
Recently other tachykinins such as neurokinin A (NKA) and neurokinin B (NKB) have also been 
recognized as the neurotransmitters of e-NANC. Substance P acts via neuropeptide receptors 
known as neurokinin 1 (NK-1) receptors, whereas NKA and NKB acts through NK-2 and NK-3 
receptors, respectively.  By employing autoradiography techniques, Sonea and co-workers have 
demonstrated that the SP binding sites in the equine lungs were very dense over small bronchial 
vessels, tracheobronchial glands and airway epithelium in large and small airways (Sonea et 
al.1999). However, the density of SP binding sites over airway smooth muscle was much lower 
than in the aforementioned tissues. These authors have also suggested that in equine lungs NK-1 
receptor density is greater compared with that of NK-2. In addition, they stated that the receptor-
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mediated effects of SP in the equine lung most likely involve regulation of vascular tone and 
airway secretions based upon the density of SP binding sites in these tissues. Furthermore, they 
concluded that the activation of intrapulmonary afferent nerves containing SP by noxious stimuli 
such as inhaled allergens or irritants may lead to increased mucus secretion and decreased airway 
diameter due to vascular congestion. The same authors have also demonstrated the distribution of 
pulmonary nerves immunoreactive for SP by using immunohistochemical methods on healthy 
lungs from adult equids (Sonea et al. 1994). The nerve fibers immunoreactive for SP were more 
frequently observed near the hilus of the lung than in the caudal lobes or in the periphery of the 
lung. In addition, these nerve fibers immunoreactive to SP were most abundant in the lamina 
propria of the trachea and larger airways, particularly within and directly below the airway 
epithelium; they were also frequently associated with bronchial and pulmonary vessels. Presence 
of nerve fibers immunoreactive for SP in peribronchial neural ganglia indicated that these 
sensory nerves may modulate parasympathetic regulation of pulmonary function. The authors 
have concluded that the nerve fibers immunoreactive for SP were well placed to detect inhaled 
agents and to contribute to the pulmonary response to irritants and pathogens.  
            In equine airways, i-NANC nerves supply the trachea and central bronchi, but are absent 
in the third generation of bronchi in the horses affected with RAO. By employing electrical field 
stimulation studies, Yu and co-workers have studied the distribution of inhibitory nerves and the 
mediator of the i-NANC system in smooth muscles of equine airways (Yu et al. 1994). They 
concluded that in equine airways, the i-NANC nerves supply the trachea and central bronchi and, 
nitric oxide (NO) mediates the i-NANC function. The functions of NO include smooth muscle 
relaxation, inhibition of smooth muscle proliferation, inhibition of platelet aggregation and 
adhesion, and act as the neurotransmitter of bronchodilator nerves. In horses acutely affected by 
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COPD, there is a consistent lack of i-NANC function in the larger bronchi (Yu et al. 1994). 
However, it is still unclear whether the reduction of i-NANC control is a result of the 
inflammatory response during acute COPD or is a basic characteristic of COPD-susceptible 
horses.  
1.4 Role of Inflammatory Mediators in the Pathogenesis of SPAOPD        
              Even though it is widely believed that inflammatory mediators play a vital role in the 
pathogenesis of RAO, there is currently a paucity of the literature regarding their exact role. 
Gray and co-workers have conducted a study to investigate the involvement of the 
cyclooxygenase products in the pathogenesis of RAO. In that study, they measured plasma and 
BALF concentrations of metabolites of thromboxane TXA-2 and prostaglandins PGI-2 and 
PGD-2 in five affected ponies and their age and gender-matched controls prior to and during 
acute airway obstruction precipitated by housing the ponies in a barn and exposing them to hay 
dust. They reported that plasma TXB-2 was the only metabolite that increased significantly 
during the acute disease state. When the ponies were treated with a cyclooxygenase inhibitor 
flunixin meglumine, TXB-2 production was inhibited but the degree of airway obstruction or 
airway hyperreactivity was not altered when measured at pasture and in the barn. They 
concluded that cyclooxygenase products of arachidonic acid metabolism are altered but do not 
play a role in the airway obstruction and hyperreactivity observed in ponies with heaves (Gray et 
al. 1989). The same investigators have measured plasma immunoreactive 15-
hydroxyeicosatetraenoic acid (i15-HETE) concentrations in carotid artery and right ventricle 
blood samples in five affected ponies and their age- and gender-matched control ponies. They 
found that the plasma i15-HETE concentrations were greater in carotid artery samples compared 
with right ventricle samples in affected ponies, suggesting that the lung was a source of i15-
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HETE. Carotid artery i15-HETE concentrations were significantly greater in affected ponies than 
in control ponies. They concluded that affected ponies produce greater quantities of i15-HETE 
than control ponies and that exposing affected ponies to a barn environment produces acute 
airway obstruction and increased plasma concentrations of i15-HETE (Gray et al. 1992a).  
             In another study, the same authors have measured PGE-2 and 15-HETE production in 
vitro in tracheal epithelium obtained from six affected horses at the time of acute airway 
obstruction as compared with six matched control horses. Strips of epithelium and subepithelial 
tissue were prepared and stimulated with histamine and bradykinin. The PGE-2 and 15-HETE 
levels were quantitated by radioimmunoassay. They found that 15-HETE above the limits of 
accurate detection was found in epithelial strips of only two principal animals and in none of the 
control horses, and the amount of 15-HETE was not increased when strips were stimulated. In 
addition, they found that the epithelial strips from affected horses tended to produce less PGE-2 
than those of control horses, and there was a significant correlation between epithelial PGE-2 
production and the time taken for affected animals to develop airway obstruction. They 
concluded that the equine tracheal epithelium is not a significant source of 15-HETE and airway 
mucosal PGE-2 production is reduced in horses with heaves, which suggests that a relative 
decrease in this bronchorelaxant substance may be a factor in the pathogenesis of RAO (Gray et 
al 1992b). Similarly, Costa and co-workers have demonstrated that the expression of inducible 
nitric oxide synthase (i-NOS) was greater in bronchial epithelial cells of horses with SPAOPD, 
compared with non-affected horses, suggesting that NO may play a role in amplifying the 
inflammatory process in the airways of horses with this disease (Costa et al. 2001). However, in 
a study conducted by Watson and co-workers, it was found that the concentrations of PGE-2 and 
PGF were significantly greater in BALF from horses with COPD than in BALF from normal 
 14
horses, but no differences were detected in TXB-2, 6-keto-PGF-1 alpha, PGD-2, LTB-4 or LTC-
4 (Watson et al. 1992). Based on the aforementioned studies, it can be inferred that while the 
excitatory prostanoids might not play a major role, inhibitory prostanoids may play an important 
role in the pathogenesis of equine RAO (Robinson et al 1996). This conclusion is supported by 
the findings of a study conducted by Yu and co-workers who demonstrated that in the bronchi of 
horses with heaves the inhibitory function of prostanoids is reduced (Yu et al. 1994). 
              The role of histamine appears to be limited in the pathogenesis of equine COPD. Even 
though the levels of histamine in the BALF of horses challenged with antigens increase when 
compared to control horses, clinical observations suggest that COPD-affected horses do not 
respond considerably to anti-histamines (McGorum et al 1993, Beech 1991). Similar findings 
were reported by Venugopal and co-workers, who demonstrated that the response of bronchial 
rings from horses with SPAOPD to 5-hydroxytryptamine (5-HT) was significantly greater than 
those from control horses, whereas the response to histamine was significantly lower (Venugopal 
et al. 2001). Benamou and co-workers conducted a study to determine the role elicited by 
endothelin-1 (ET-1), a potent smooth muscle constrictor and inflammatory mediator, in the 
pathogenesis of RAO (Benamou et al. 1998). In this study, they investigated the levels of ET-1 
in systemic blood as well as in BALF from horses with RAO. They also studied how these 
values might correlate with those of lung function tests and pulmonary artery pressure. The RAO 
horses had significantly greater systemic ET-1 levels than control horses. They also had a 
negative arteriovenous ET-1 difference that may correspond to a net uptake of ET-1 in the lung. 
The RAO horses in crisis had increased amounts of immunoreactive ET-1 in BALF compared to 
normal control subjects. Additionally, the reduction in lung function observed in RAO horses in 
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crisis was significantly correlated with lower epithelial lining fluid ET-1 levels. Finally, they 
suggested that ET-1 may play an important role in the pathogenesis of RAO.  
              In a study conducted by Olszewski and co-workers, it was concluded that inflammatory 
mediators can increase endogenous cholinergic responses of equine airways via both 
prejunctional and postjunctional mechanisms (Olszewski et al. 1999). They found that LTD-4 
acts solely on smooth muscle, whereas 5-HT and histamine additionally act on neuronal 
receptors to facilitate release of ACh. In addition they also concluded that the excitatory effects 
of histamine, including the direct contractile effect and augmentation of the endogenous 
cholinergic response, are both mediated via H-1 receptors, whereas the inhibitory H-3 receptors 
partially oppose the direct contractile effect of this mediator. Therefore, inflammatory mediators 
play an important role in the alteration of neural control of airways in RAO.   In another study 
performed by the same authors, it was demonstrated that in equine small airways; 1) the 
endogenous cholinergic responses are subject to strong facilitation by inflammatory mediators, 
2) activated neutrophils do not affect cholinergic responses; and 3) in acute episodes of equine 
COPD, histamine, LTD-4 and serotonin (mediators primarily associated with type I allergic 
reactions) rather than mediators derived from neutrophils most likely contribute to increased 
cholinergic airway tone.            
             On the whole, it can be inferred that various inflammatory mediators might play major 
roles in the pathogenesis of equine RAO. Therefore, any significant finding in this discipline 





1.5 Introduction to Endothelin-1 
            In 1985, Hickey et al demonstrated that the culture media obtained from bovine aortic 
endothelial cells cause progressive dose-dependent increments in the isometric tension of 
porcine, bovine and canine coronary arteries (Hickey et al. 1985). Discovery of this novel 
peptidergic endothelium-derived contraction factor (EDCF), a vasoactive peptide, initiated a new 
area in the field of biomedical sciences, which promised a clear and better understanding of 
pathogenesis of several important diseases. This peptide was subsequently isolated from porcine 
aortic endothelial cells, sequenced, cloned and named endothelin-1 (ET-1) by Yanagisawa in 
1988. There are three distinct human endothelin-related genes encoding for the three related, but 
distinct isomers of endothelins: a) the predominant endothelin (ET-1), b) endothelin-2 or ET-2 
(with Trp and Leu at 6th and 7th positions, respectively), and c) endothelin-3 or ET-3 (with Thr, 
Phe, Thr, Tyr, Lys and Tyr at positions 2,4,5,6,7 and 14, respectively) (Inoue et al. 1989) (figure 
1.1). Another peptide belonging to the endothelin family was cloned in mice and was named 
vasoactive intestinal contractor (VIC or ET-4) (with Asn, Trp and Leu at positions 4, 6 and 7 
respectively) (Saida et al. 1989, Luscher and Barton 2000). In addition, a 31 amino acid residue 
ET-1 has also been identified (Nakano et al. 1997, Kishi et al. 1998, Goldie et al. 2000). All the 
four isoforms of endothelin possess 21 amino acids and an identical hydrophobic C-terminal 
hexapeptide (Ohlstein and Ruffolo Jr. 1995).  
Among all ET isoforms, ET-1, which has a molecular weight of 2,492 daltons, plays a 
pivotal role in various physiological as well as pathological processes (Ohlstein and Ruffolo Jr. 
1995).  It is the only isoform synthesized in the vascular endothelium and is now considered to 
be the most potent vascular smooth muscle constrictor in mammals (White et al. 1991). Upon 
systemic administration, ET-1 causes more prolonged elevation in blood pressure than any other 
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vasoconstrictive peptide known to date (D’Orleans-Juste et al. 2003). The ET-2 has renovascular 
functions and is found in the myocardium, kidney and placental tissues (Fagan et al. 2001). The 
ET-3 has neurotransmitter functions and is found in the central nervous system, gastrointestinal 
tract, lung and kidney (Fagan et al. 2001, Spyer et al. 1991). 
ET-1 has an influence on DNA synthesis, the expression of cancer genes, cell 
proliferation and cellular hypertrophy.  Mitogenesis caused by ET-1 involves activation of 
complex and multiple transduction pathways, such as the production of second messengers, the 
release of intracellular pools of calcium, and influx of extracellular calcium. ET-1 acts 
synergistically with various regulatory and growth factors, such as epidermal growth factor 
(EGF), platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), 
transforming growth factor (TGF), etc., to regulate cellular transformation and replication (Dube 
et al. 2000). Several of these factors in turn stimulate the synthesis and release of endothelins. 
The synthesis and release of endothelins are also increased in acute and chronic pathological 
conditions such as atherosclerosis, postangioplastic restenosis, hypertension, and carcinogenesis 
(Battistini, et al. 1993).                        
1.6 ET-1 Biosynthesis 
  Similar to all the other functional peptides in the body, ET-1 is synthesized from a large 
inactive precursor protein. This precursor (preproendothelin-1 or PPET-1) is cleaved 
enzymatically by different proteolytic enzymes, finally leading to the synthesis of ET-1 (Itoh et 
al. 1988). Human PPET-1 contains 212 amino acids and porcine PPET-1 contains 203 amino 
acids (Yanagisawa et al. 1988). In most processing steps, cleavage of the inactive PPET-1 
occurson the carboxyl side pairs of basic amino acids, usually Lys-Arg or Arg-Arg or Arg-X-X-
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Arg, followed by the removal of basic amino acids by carboxypeptidases (Denault et al. 1995). A 






Figure 1.1− Structures of ET family members 
is involved in cleaving these basic amino acids (Blais et al. 2002). ET-1 is derived from PPET-1 
residues 53-73, which are preceded by paired basic amino acids (Bloch et al. 1989). First, a 
signal peptide is removed from the PPET-1 by a signal peptidase in the lumen of rough 
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endoplasmic reticulum, yielding a precursor of 195 amino acids, proendothelin-1 (pro-ET-1) 
(Denault et al. 1995). Pro ET-1 contains six potential recognition sequences (Arg-X-X-Arg 
cleavage sites named as R1a, R1b, R2, R3, R4 andR5) for members of SPCs. This peptide is 
converted to 38 (human) or 39 (porcine) amino acid big ET-1-Lys-Srg, by the furin convertase 
and PC7, which are the members of SPCs (figure 1.2). Furin convertase has better efficiency 
than PC7. Pro-ET-1 is the only member of the ET family that contains six potential convertase 
cleavage sites, three being located in the C-terminal fragment. Pro-ET-2 contains one cleavage 
site in its COOH-terminal, whereas the ET-3 precursor does not have a carboxy terminal. 
Conversion of big ET-1 in to the biologically active ET-1 is believed to occur via specific 
metalloproteases called endothelin converting enzymes (ECE). The ECE cleaves the C-terminal 
halves of big ET-1 between Trp21 and Val/Ile22, yielding the N-terminal, 21-residue active 
endothelins (Emoto and Yanagisawa 1995). The ET-1 has 140-fold more powerful 
vasoconstricitve properties than big ET-1 and pro-ET-1 has no vasomotor action (Kimura et al. 
1989). 
1.7 Endothelin Receptors 
1.7.1 Introduction – Maggi and co-workers performed the first pharmacological studies to 
characterize endothelin receptors. They confirmed the existence of two distinct receptors and 
named them ET-A and ET-B. They also reported that in ET-B receptors, the free acid of 
tryptophan in position 21 plays a key role in the activity of endothelins (Maggi et al. 1989). 
Subsequently, existence of multiple receptor subtypes was shown in various human and porcine 
tissues by ligand and affinity binding studies (Takayanagi et al. 1991). Many groups have cloned 
these two receptors in various species, including humans (Arai et al. 1990, Sakurai et al. 1990, 
Baynash et al. 1994, Nakamuta et al. 1991, Lin et al. 1991, Adachi et al. 1991). 
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NH2-- -              -Gly-Ala-                               -Lys-Arg-                                       --Lys-Arg -                                  -COOH 
        1          17                   20                               50                    53              74    84      90               93                                    202 
                                                                                 Prepro ET-1 
 
 
                                                                           1                21     31    38                                                                    
                                                                                    Big ET-1 
 
                                 1              21                                   1                    31 
                                    ET-1                                   ET-1 (1-31)   
 
Figure 1.2 − Biosynthesis of ET-1 and ET-1 (1-31) from preproendothelin-1 
To date, four types of ET receptors have been cloned and characterized. Mammals possess ET-A 
and ET-B receptors (Arai et al. 1990, Lin et al. 1991, Sakurai et al. 1990, Sakamoto et al. 1991). 
The ET-C receptor, which is sensitive to ET-3, is found in frogs (Karne et al. 1993). This 
receptor has 47 and 53% primary amino acid sequence identity to the mammalian ET-A and ET-
B receptors, respectively. The fourth type of receptor was discovered in rats and named ‘dual 
angiotensin II/ET-1 receptor’ (Ruiz-Opazo et al. 1998). Discovery of this dual receptor provided 
evidence of a molecular link between the ET-1 and angiotensin II hormonal systems. In addition 
to the above mentioned types of ET receptors, some other subtypes were also discovered in 
various species. For example, a novel subtype of ET-B receptor was discovered in birds (Lecoin 
et al. 1998). Another receptor called as ET-AX has been cloned and characterized in Xenopus 
leavis heart (Kumar et al. 1994). The other receptor that was found in Xenopus leavis liver was 
   Signal peptidase, PC7 & Furin Convertase          
ECE Chymase
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named ET-BX. These receptors resemble mammalian ET-B receptors in their affinities for ET-1 
and ET-3 (Nambi et al. 1994). All the aforementioned types and subtypes of ET receptors are 
comparatively similar in size, ranging from 415 to 444 amino acid residues. The regions of 
greatest similarity are found in the transmembrane region and the regions of greatest diversity are 
found in extramembranous amino and carboxy termini (Derk et al. 1995).  The affinity of ET-A 
receptors for ET-1 and ET-2 is over 100-fold greater than for ET-3, whereas ET-B receptors bind 
ET isopeptides with similar affinity (Masaki 1995). This explains why ET-B is referred as a non-
isopeptide selective receptor. Cross-talk between ET-A and ET-B receptors has been reported; 
however, whether or not this cross-talk affects receptor function is unknown (Simonson and 
Herman 1993, Ozaki et al. 1997, Zahradka et al. 1998). Many pharmacological studies on blood 
vessels have indicated the existence of a subtype of ET-A receptors (Bax et al. 1993, Salom et al. 
1993, Clark and Pierre 1995 and Maguire et al 1996). Similar results were obtained from 
pharmacological studies in isolated human bronchus and isolated sheep bronchus (Hay et al. 
1998, Henry and King 1999). However, radio ligand binding studies on blood vessels and 
isolated sheep bronchus have shown contradictory results (Maguire et al. 1996, Henry and King 
1999). For the ET-B receptor, a further division into ET-B1 and ET-B2 receptors has been 
suggested in human bronchus and blood vessels, and rat brain and atrium (Sokolovsky et al. 
1992, Hay et al. 1998). The ET-B1 receptor is principally found on endothelial cells and causes 
vasodilatation because of the formation of NO and /or prostacyclin. The ET-B2 receptor is 
present on the smooth muscle cells where it mediates vasoconstriction and bronchoconstriction.     
1.7.2 Structure of ET Receptors – The structure of mature ET receptors has been deduced from 
the nucleotide sequences of the DNAs. Both ET-A and ET-B receptors contain seven 
transmembrane stretches of 20 to 27 hydrophobic amino acid residues and belong to the seven-
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transmembrane (7 TM) domained, heterotrimeric G-protein coupled rhodopsin type receptor 
super-family. Human ET receptors have several amino acid residues and sequence motifs shared 
by other members of the G-protein receptor superfamily, including cysteines at position 158 and 
239 (ET-A) and 174 and 255 (ET-B), which are postulated to cross link extracellular loops 1 and 
2 by a sulfide bond. Both ET-A and ET-B receptors are heptahelical receptors having an N-
terminal signal sequence with relatively long extra-cellular N-terminal portion preceding the first 
transmembrane domain. There are two separate ligand interaction subdomains in each of the ET 
receptors. The extracellular loops, particularly between TM 4 to 6, determine selectivity 
(Davenport 2002).  In general, ET receptors have one hydrophobic extracellular amino terminal 
sequence, three putative extracellular loops, three intracellular loops and a carboxy terminal. 
Four cysteine residues are present in the amino terminals and also three cysteines in each of the 
three extracellular loops (Derk et al. 1995).  
             The activation of ET-A receptors induces long-lasting vasoconstriction and cell 
proliferation in different tissues (Pollock et al. 1995, Ohlstein et al. 1992). In contrast, the 
activation of endothelial ET-B receptors stimulates the release of NO and prostacyclin, prevents 
apoptosis, and inhibits ECE-1 expression in endothelial cells (Warner et al. 1989, Hirata et al. 
1993, Shichiri et al. 1997, Luscher and Barton 2000). The ET-B receptors also mediate the 
pulmonary clearance of circulating ET-1 and the re-uptake of ET-1 by endothelial cells 
(Fukuroda et al. 1994, Ozaki et al. 1995). The human ET-A receptor is 427 amino acids long 
with a MW of 48,516 daltons. The human ET-B receptor has 442 amino acids and has a 
molecular weight of 46,901 daltons. There is 58.9% homology between these two receptors in 
humans (Table 1.1) (Elshourbagy et al. 1993). The degree of homology between human ET-A 
and ET-B receptors occurs more in the transmembrane hydrophobic domains (86-96%) 
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compared with the extracellular domains (65-83% in extra cellular loops and 50% in carboxy 
termini) (Ohlstein et al. 1995, Elshourbagy et al. 1993). The human ET-A receptor has 94% and 
91% primary amino acid sequence identity with bovine and rat ET-A receptors, respectively 
(Elshourbagy et al. 1993, Cyr et al. 1991). The ET-B receptor shares 90%, 89% and 88% identity 
with porcine, bovine and rat ET-B receptors, respectively (Elshourbagy et al. 1993, Ohlstein et 
al. 1995). Equine ET-B receptors are 443 amino acids long and shares 89, 91 and 85% homology 
with human, bovine and mouse ET-B receptors, but it is only 55% identical with human, bovine 
and rat ET-A receptors (Yang et al. 1998). Bovine lung ET-B receptor is 441 amino acids long; 
26 constitute an NH2-terminal signal peptide and 415 constituting the mature receptor (Saito et 
al. 1991). In general, ET receptors have a large extracellular amino terminal region which plays 
an important role in tight binding to ET (Kemp and Pearson 1990). But this is not the case with 
the bovine ET-B receptor, which has no sequence homology at the NH2 terminal either with 
bovine ET-A receptors or any other subtypes of ET-B receptors (Saito et al. 1991). It has 63 and 
85% homology with bovine ET-B and rat ET-B receptors, respectively (Saito et al. 1991). ET-
AX receptor has 415 amino acids and has 61, 74, 60, 51, 72, and 74% homology with porcine 
ET-B, human ET-A, ET-B, Xenopus ET-C, bovine and rat ET-A receptors, respectively 
(Elshourbagy et al. 1992, Elshourbagy et al. 1993, Arai et al. 1990). Like other ET receptors, it 
also has a leader sequence, a large extracellular domain (70 amino acids long) and a short third 
cytoplasmic loop (29 amino acids) (Kumar et al. 1994). Transmembrane domains IV-VI and 
adjacent loops are important for ET-B selective pharmacology, where as transmembrane 
domains I, II, III and VII plus intervening loops are essential for ET-A selective pharmacology 
(Sakamoto et al. 1993).  It is suggested that tight association of ET with its receptor is due to a 
strong interaction of its hydrophobic domain with the membrane lipids and/or its internalization 
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within cells (Hirata et al. 1989a). Endothelin receptors as with other cell surface receptors are 
subject to ligand-induced down-regulation. Exposure of cultured smooth muscle cells and 
cardiocytes to ET-1 for 18-24 hours caused a marked decrease in ET-1 binding sites and no 
significant change in affinity (Hirata et al. 1989a, Hirata et al. 1989b, Ohlstein et al. 1995). 
 
Table 1.1 – Homology of the amino acid sequences of ET-A and ET-B receptors among various 
mammalian species. 
 
Species ET receptor 
type 
Amino acids Percentage of 
homology 
ET-A  427 58.9 ET-B (Hu) 
91 ET-A (Rat) 
Human 
ET-B  442 89 ET-B (Bo) 
89 ET-B (Eq) 
ET-A 427  Porcine 
ET-B 443 90 ET-B (Hu) 
ET-A 427 55 ET-B (Eq) 
94  ET-A (Hu)  
Bovine 
ET-B 441 91 ET-B (Eq) 
ET-A 426 55 ET-B (Eq) Rat 
ET-B 442 88 ET-B (Hu) 
Equine ET-B 443 55 ET-A (Hu) 
Mouse ET-B 442 81 ET-B (Eq) 
 
           Once the endothelin receptor complex has been formed, the complex undergoes rapid 
internalization into lysosomal compartments where the acidic environment promotes ligand 
disassociation (Hirata et al. 1989b, Marsault et al. 1991a, Marsault et al. 1991b). Thus, the 
receptors are recycled. It is also proved that endothelin receptors exist intracellularly, mostly in 
the Golgi complex and nuclei. Even though the density of these receptors in Golgi is much less 
(<10%), it can be suggested that a recycling pathway for these receptors exists inside the cell 
(Hocher et al. 1992). The recycled receptors are migrated to the plasma membrane through a 
cycloheximide-insensitive pathway. Endocytotic recycling and externalization of ET receptors 
comes from the observation that both dansylcadavarine (a transglutamate inhibitor) and 
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phenylarsine oxide (a recycling inhibitor) inhibit the recovery of endothelin-binding sites in the 
plasma membrane following exposure to ET-1 (Marsault et al. 1993, Resink et al. 1990).  
1.7.3 ET Receptor Genes – The genes for human ET-A and ET-B receptors are located on 
chromosomes 4 and 13, respectively (Masaki 1995). The gene of ET-A receptors spans more 
than 40 Kb of DNA and that of ET-B receptor spans approximately 24 Kb of DNA. Having such 
large genes is typical of proteins belonging to the G-protein coupled receptor family. The ET-A 
receptor gene is expressed as a single mRNA transcript of 4.3 Kb (Hosoda et al. 1991). The ET-
B receptor gene is predominantly expressed as two mRNA molecules that are 4.3 and 1.7 Kb in 
length. A third ET-B receptor mRNA transcript, 2.7 Kb in length is also present in placental 
tissue (Ogawa et al. 1991). These three different transcripts may arise from alternative 
polyadenylation of the ET-B mRNA, which would not effect the final translation of the ET-B 
receptor. Alternatively, the multiple ET-B mRNA species may reflect alternative splicing of the 
precursor mRNA, which could potentially give rise to structural variants (subtypes) of the ET-B 
receptor protein (Shyamala 1994, Cheng et al. 1993). The human ET-A receptor gene contains 
eight exons and seven introns and the ET-B receptor gene comprises 7 exons and 6 inrons. The 
structural organization of the genes of both receptors is essentially the same. The only major 
difference is that the human ET-B receptor gene lacks an intron corresponding to intron 1 of the 
human ET-A receptor gene, which is present on the 5’ non-coding region. Furthermore, these 
two genes share an intron at the same position immediately after the third transmembrane 
domain. Thus, the intron phase and the nucleotide sequence around the exon-intron splice site are 
highly conserved. The 5`-flanking regions of both genes lack typical TATA and CCAAT boxes 
but contain  Sp1 transcription factor binding sites, GATA binding motifs and APPRE sequences 
that induce mRNA expression under acute stress in vivo. All of these results suggest that both 
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receptors evolved from a common ancestral gene (Arai et al. 1993). Despite these similarities, 
the tissue specific patterns of expression of these two genes are quite different (Rubanyi and 
Polokoff 1994).  
1.8 Mechanism of Action of ET-1 
           All endothelin isoforms elicit various biological actions by binding to specific receptors 
located on the external surface of the cell membrane. This binding activates complex but highly 
coordinated signal transduction pathways involving various secondary intracellular messengers 
which activate enzymes such as kinases and phophstases and in turn phosphorylate or 
dephosphorylate key cellular proteins, leading ultimately to biological responses. The coupling 
of endothelin receptors to intracytoplasmic and plasma membrane effector molecules occurs 
through a family of GTP (guanosine triphophate) binding proteins known as guanine nucleotide 
regulatory proteins or G-proteins. G proteins are heterodimers and have three subunits, namely 
α,β and γ. The  α subunits bind to guanine nucleotides and the β γ  complex functions as a single 
unit. As many as twenty α subunits, at least four β subunits, and six γ subunits and their 
respective genes have been isolated and characterized. Endothelin and receptor complex generate 
an interaction between the receptors and G-proteins on the intracellular surface of the membrane. 
This interaction promotes disassociation of GDP from the α subunit and stimulates association of 
GTP to it, resulting in the disassociation of α subunit from the β γ complex. The released α -GTP 
subunit regulates the activity of secondary messengers. The α subunit also shows endogenous 
GTP-ase activity resulting in the inactivation of the cycle. The β γ complex is also involved in 
direct modulation of secondary mediator molecules such as adenylate cyclase, phosholipase C, 
phospholipase A2 and K+ channels. A single G-protein can activate multiple effectors, and a 
single receptor can couple to multiple G proteins to activate single or multiple effector systems. 
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Differential expression of ET receptor subtypes and their coupling to single or multiple G 
proteins can result in the activation of selective pathways that are appropriate for the biological 
responses in different tissues. 
1.8.1 Secondary Mediators Involved in Endothelin-Mediated Signal Transduction –          
Calcium: It is believed that ET-1 stimulates Ca+2 influxes into vascular smooth muscle cells via 
non-dihydropyridine-sensitive Ca+2 channels. Many of the antagonist studies have shown that 
Ca+2 channel blockers such as verapramil, nifedipine and nicardipine markedly attenuate ET-1 
induced vasoconstriction (Egashira et al. 1990, Encabo et al. 1992, Luscher et al. 1990, Kasuya 
et al. 1989, Hardebo et al. 1989, Lougee et al. 1990, Takenaka et al. 1992). However, in some 
other studies no such attenuation was observed (Wallnofer et al. 1989, Blackburn and Highsmith 
1990, Chabrier et al. 1989, Bodelsson et al. 1992). Dosages of ET-1 and Ca+2 channel 
antagonists and the sources of the blood vessels and smooth muscle cells used in these 
experiments could have lead to this contradiction.  It is believed that ET-1 induces smooth 
muscle contraction by increasing intracellular Ca+2 levels (Figure 1.3). There are two possible 
mechanisms for this increase. First, a rapid and transient initial phase in which calcium is 
mobilized from intracellular stores. ET-1 stimulates an increase in inositol 1-4-5 trisphosphate 
(IP3) which causes increased mobilization of intracellular calcium (Little et al. 1992). The 
second sustained phase is dependent upon extracellular calcium influx into the cell. ET-1 is not a 
ligand to L type Ca+2 channels. It causes Ca+2 influx through indirect actions. One of the 
possible mechanisms is membrane depolarization. The most important cause attributed for this 
depolarization is activation of chloride channels. Increase in intracellular sodium levels either by 
inhibition of Na+/K+ ATP-ase or by stimulation of the Na+/H+ antiporter, is also another 
mechanism of depolarization. In addition to membrane depolarization, platelet activating factor 
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(PAF) and TXA-2 also mediate Ca+2 uptake (Takayasu et al. 1989). Influx of extracellular 
calcium also triggers calcium release from intracellular stores (Gardner et al 1992). It is also 
reported that ET-1 can cause smooth muscle cell contractions by altering the sensitivity of the 
myofilaments to calcium.  That means, even if the intracellular calcium levels are not increased 
either by influx or mobilization from intracellular stores, ET-1 can cause smooth muscle cell 
contraction. This is believed to occur through a G-protein dependent pathway probably involving 
PKC (Nishimura et al. 1992). 
           Inositol-3-Phosphate (IP3) and Diacylglycerol (DAG): Numerous reports indicate that 
ET-1 stimulates phospholipase-C (PLC) mediated hydrolysis of PI (phoshpatidylinositol 4, 5-
biphosphate) resulting in the rapid transient formation of IP3 and more sustained DAG 
generation in smooth muscles. In addition to IP3, a variety of other inositol phosphates such as 
inositol tetrakisphosphate may be formed by ET-1 (Simonson et al. 1989).  DAG is formed 
mainly by hydrolysis of IP3. However, it can be formed by the hydrolysis of phosphatidylcholine 
by PLC and degradation of phasphatidic acid by phosholipase D also. IP3 is responsible for the 
stimulation of release of calcium from intracytoplasmic sarcoplasmic reticulum and calcisome 
(Bialecki et al. 1989, Hirata et al. 1989a). Neutral DAG on the other hand, mediates ET-1 
induced activation of phosphokinase-C. Inositol tetrakisphosphate acts in synergy with IP3 to 
stimulate an increase in calcium in ET-1 stimulated cells.  
          Phosholipase-D (PLD): Application of endothelins to rat mesangial cells, VSMCs and 
fibroblasts result in activation of PLD, which hydrolyzes phospholipids, such as 
phosphatidylcholine and phoshphatidylethanolamine, to produce phosphatidic acid and either 
choline or ethanolamine, depending on the phospholipids involved. ET-1 activates PLD in both 
PKC - dependent and - independent pathways (MacNulty et al. 1990). 
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Figure 1.3 − Mechanism of action of ET-1 
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          Protein kinase-C (PKC):  Several studies using activators (phorbol esters) and inhibitors 
of PKC (staurosporin) provided evidence that activation of PKC plays a role in ET-1 mediated 
vascular contraction. PKC, a Ca+2 and phospholipid dependent enzyme, can be activated by 
DAG and tumor promoting phorbol esters (Nishizuka 1989). 
         Adenylate Cyclase: In contrast to the activation of PLC and generation of inositol 
phosphates, cyclic nucleotide levels are generally unaffected by ET-1 (Sugiura et al. 1989). 
However, in the iris sphincter of various species, such as cat, dog, cow, monkey and human,   
ET-1 has been shown to increase cAMP formation (Abdel-Latif and Zhang 1991). This increase 
is not by the direct action but by indirect actions of ET-1, either by the activation of PLC or 
PGE-2 dependent pathway (Tomita et al. 1990, Simonson et al. 1990). 
          Guanylate Cyclase: Reiser and coworkers have demonstrated that in mouse 
neuroblastoma/rat glioma hybrid cells, the addition of ET-1 caused an increase in cGMP levels 
that was dependent on calcium presence (Reiser et al. 1990). This increase in rat glomeruli was 
mediated by ET-B receptors and was blocked by the addition of L-arginine, a NO synthase 
inhibitor, suggesting that cGMP stimulation by ET-1 was mediated through NOS (Edwards et al. 
1992).  
           Phospholipase A2 (PLA2) and Arachidonic Acid Metabolites: ET-1 stimulates 
arachidonic acid metabolism via activation of phosholipase A2 (De Nucci et al. 1988a). It causes 
release of PGI-2 and TXA-2 from isolated perfused rat and guinea pig lung preparations. ET-1 
also mediates release of prostaglandins in kidney, intestine and ion secretion in liver, eye, 
airways and, gestational tissues (Brown and Smith 1991, Gandhi et al. 1992, Granstam et al. 
1991, Ninomiya et al. 1992, Mitchell et al. 1990).  
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           Na+-H+ Exchange: ET-1 promotes intracellular alkalinization by promoting Na+-H+ 
exchange. A wide variety of agonists that are linked to PLC activation and to Ca+2 mobilization 
increase intracellular pH via PKC - mediated activation of Na+-H+ exchange by increasing the 
intracellular H affinity for the antiporter (Grinstein and Rothstein 1986). This is also true with 
ET-1 (Lonchampt et al. 1991).  
1.8.2 Effects on Gene Expression – ET-1 regulates gene expression to evoke long-lasting 
cellular responses. It stimulates the expression of the immediate early response genes c-fos and 
c-myc in vascular smooth muscle cells (Komuro et al. 1989). In rat-1 fibroblasts, ET-1 rapidly 
increased mRNA levels of five members of the fos / jun gene family (c-fos, fos-B, fos-1, c-jun 
and jun-B) (Pribnow et al. 1992). For c-fos induction, calcium influx is necessary. And one of 
the important mechanisms by which calcium promotes c-fos incduction is via CaMK 
(calmodulin dependent protein kinase) (Wang and Simonson, 1996). ET-1 is reported to have 
activated the enzyme mitogen activated protein kinase (MAPK) in cultured ventricular 
cardiomyocytes and in cultured vascular smooth muscle cells (Bogoyevitch et al. 1993, Koide et 
al. 1992). ET-1 also stimulates DNA synthesis, protein synthesis and /or proliferation in 
pulmonary artery smooth muscle cells and in rat 6 fibroblasts (Janakidevi et al. 1992). ETs can 
participate in long term adaptive changes in various tissues, including vascular remodeling, 
cardiac hypertrophy, and bone remodeling, and also in the pathogenesis of proliferative 
disorders, such as atherosclerosis, renal diseases and bronchial asthma. ET-1 evokes nuclear 
signaling cascades leading to differential expression of genes that control cell growth and/or 
differentiation. The c-Src or Src family of protein-tyrosine kinases contributes to a nuclear 
signaling cascade, linking ET-1 receptors to the c-fos promoter. Activation of the c-fos promoter 
by ET-1 requires both the CArG box of the serum response element (SRE) and the Ca/CRE 
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(calcium response element). Src participates in the ET-1-Ras-c-fos CArG Box Signaling Cascade 
(Simonson et al. 1996).  
1.9 ET-1 and Lungs 
             Among various organ systems in the body, the lung has the greatest levels of ET-1 
secreted by pulmonary vascular endothelium, smooth muscle, airway epithelium and a variety of 
other cells. Immunoreactivity for ET-1 can be detected in pulmonary endocrine cells of 
developing human lung, in the airway epithelium, pulmonary vascular endothelial cells, clara 
cells (alveolar type II pneumocytes), goblet cells, neuroendocrine cells, smooth muscle cells, 
platelets, mucus cells, serous cells, parasympathetic ganglia within the airways, and alveolar 
macrophages (McKay et al., 1991a, Rozengurt et al. 1990, Giaid et al. 1991). Most of the non-
ciliated cells synthesize endothelins rather than basal and ciliated cells (Giaid et al. 1991). 
Finding of ET-1 and ET-2 on parasympathetic ganglia suggested a neuromodulatory role for 
these peptides in the lungs (McKay et al. 1991a). ET-3 also was found to have a 
neuromodulatory role on cholinergic parasympathetic transmission in rabbit airways exerted at a 
prejunctional site (McKay et al. 1993).  The ECE and endothelin degrading enzymes also coexist 
in the airway tissue and both enzymes are sensitive to phosphoramidon. Levels of ECE are 
elevated in patients with chronic rhinitis and idiopathic pulmonary fibrosis (Furukawa et al. 
1996, Noguchi et al. 1991). The presence of immunoreactive ET-1 and its abundant binding sites 
in airways and the finding that ET-1 is secreted toward both the luminal side and the serosal or 
abluminal side of the airways suggested that this peptide is an important autocrine and/or 
paracrine modulator of airway functions (Blouquit et al. 2003). Elevated levels of ET-1 in BAL 
and plasma of patients with various airway diseases and reduction in the symptoms when 
endothelins, endothelin forming enzymes and their receptors are antagonized provides evidence 
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that these peptides are not only important in normal physiology but also in pathogenesis of lung 
diseases. It is already established that endothelins cause sustained and powerful contraction of 
the airway smooth muscle in vivo and in vitro directly and indirectly.  ET-1 also acts on airway 
epithelium. It increases ciliary beat frequency, activates mucus secretion by submucosal glands, 
and stimulates proliferation of epithelial cells. In humans, ET-1 stimulates lactoferrin and mucus 
glycoprotein release from serous and mucus cells in cultured nasal mucosal explants, and affects 
expression of genes such as that of fibroectin in bronchial epithelial cells. In feline trachea, ET-1 
induces mucus glycoprotein secretion via ET-A receptors, promoting Ca2+ influx into the cells; 
however, ET-2 and ET-3 have no such effect (Shimura et al. 1992).  Intranasal administration of 
ET-1 in allergic and non-allergic subjects induces symptoms of rhinoerrhea and increases the 
amount of secretions. ET-1 induces secretion of chlorides in airways of dogs, sheep and humans. 
In humans, this effect is caused by increasing the intracellular levels of cAMP and not by 
increasing calcium levels, where as in dogs this effect is the result of increased intracellular 
levels of cAMP, calcium and cyclooxygenase products such as PGE-2. Receptor antagonism 
studies have proved that ET-1 causes all of these effects on chloride secretion by acting via ET-B 
receptors (especially those located in the apical membrane of the epithelial cells) and not through 
ET-A receptors (Blouquit et al. 2003). 
1.10 ET Receptor Localization, Distribution and Functions in the Lungs 
 All of the effects of ET-1 in the airways are mediated via stimulation of ET-A and ET-B 
receptors that are widely but differentially distributed throughout the lungs. They are mainly 
located in the airway epithelium, airway smooth muscles, inflammatory cells, alveolar septa, 
vascular endothelium of pulmonary blood vessels, mucosal glands and lung parenchyma. Both 
receptors have different but important functions in different regions of the lungs in different 
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species. Takimoto and coworkers demonstrated that ET-1 induces DNA synthesis in human lung 
cell lines predominantly through ET-A receptors, via pertussis toxin-insensitive G protein 
(Takimoto et al. 1996). However, intracellular cAMP (also formed by ET-A receptors) inhibits 
this DNA synthesis. Stimulation of ET-B coupling to Gi protein modulates ET-A mediated DNA 
synthesis by inhibiting cAMP formation. This suggested that ET-B receptors do not play a 
dominant role in ET-1 induced smooth muscle mitogenesis. In contrast to ET-1, ET-3 did not 
reveal any stimulation of DNA synthesis (Takimoto et al. 1996).  
In rabbit airways, ET-1, by activating ET-B receptors, triggers the influx of extracellular 
calcium through voltage-dependent channels, and induces a contractile response that is, in part, 
dependent upon stimulation of PKC. The same mechanism is triggered in dog bronchus; 
however, the receptors involved in this species are of ET-A type. In human airways, the 
contractile response to ET-1, while independent of extracellular calcium influx, is dependent 
upon PKC activation after binding of the peptide to ET-B receptors (McKay et al. 1996). This 
suggests that considerable species variation in receptor functions exists in lungs. In general, ET-
A receptors are found more in bronchi and pulmonary vascular smooth muscles, whereas ET-B 
receptors are more in the lung parenchyma and vascular endothelium. In dogs, Dupius and 
coworkers have shown that ET-B receptors play an important role in the pulmonary elimination 
of ET-1 (Dupuis et al. 1996a).  They also found similar results in rat lungs. The endothelin-
induced potentiation of parasympathetic neural responses in the rabbit bronchus is mediated via 
ET-B receptor activation. Confirmation of ET-B receptor involvement in the neuropotentiation 
was obtained by demonstration of a significant amelioration of the potentiation in the presence of 
the ET-B receptor selective antagonist BQ-788 (McKay et al. 2000).  In guinea pig tracheal 
epithelial cells, the ET-B receptors are exclusively located on the apical membranes of the 
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ciliated columnar cells. There exists a marked species difference in the relative proportions of 
ET-A and ET-B receptors present in the airway smooth muscles, ranging from almost pure 
populations of ET-A receptors present in the ovine tracheal smooth muscles through to 
predominance of ET-B receptors in guinea pig bronchus (Goldie et al. 1994, Hay et al. 1993b). 
Human bronchial smooth muscle from non-diseased lungs contains a greater proportion of ET-B 
receptors than ET-A, where as tracheal smooth muscles from rats and mice contain 
approximately equal proportions of the two receptor subtypes (Henry 1999). Significant regional 
variation in receptor distribution is also present. For example the ratio of A to B receptors on 
airway smooth muscles changes from 30:70 to 70:30 upon moving from the trachea to the 
bronchus in the porcine airway (Goldie et al. 1996). The ratios are 30:70 and 90:10 in peripheral 
lungs of non-asthmatic and asthmatic lungs, and in human pulmonary artery, respectively (Hay 
1999). On the alveolar wall tissue of human lung, ET-A and ET-B receptors are in the ratio of 
30:70 (Knott et al. 1995). ET-1 induced contractions in both large and small sized isolated 
human bronchi are ET-B mediated (Goldie et al. 1995). These receptors are primarily linked to 
intracellular release of calcium rather than influx of extracellular calcium (McKay et al. 1991b). 
In human airway smooth muscle cell cultures, the proliferative responses to ET-1 are mediated 
via ET-A receptors, even though it is only to a small extent (Panettieri et al. 1996). However, 
ET-1 is a powerful co-mitogen, enhancing the mitogenic response to EGF several fold (Panettieri 
et al. 1996). Interestingly, ET-1 interacts with EGF-induced mitogenic axis via a pertussis toxin 
sensitive Gi protein-dependent pathway, which appears to be distinct from its direct mitogenic 
pathway (Fujitani et al. 1997).  In rat, rabbit and murine airways, the neuro-modulatory action of 
ET-1 is mediated via the stimulation of ET-A and ET-B receptors located prejunctionally and 
linked to the enhanced release of Ach during nerve stimulation (Knott et al. 1996). Although 
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only ET-B receptors have hitherto been ascribed with such a role in human airways (Fernandes 
et al. 1996), recent studies suggest that both ET-A and ET-B receptors facilitate parasympathetic 
neuro-transmission in airways of rat, rabbit and mouse trachea (Goldie et al. 1996). ET-B 
receptors have also been detected immunocytochemically in the parasympathetic neurons of 
guineapig airways (Fernandes et al. 1998). Airway epithelial cells are the major cellular sources 
of ET-1 in the airway wall. ET-1 depresses tracheal mucus velocity in sheep (used as an index of 
mucociliary clearance) via an action on ET-A receptors that was independent of prostanoids and 
peptidoleukotrienes (Sabater et al. 1996). The ET-A receptor mediated up-regulation in gene 
expression and release of fibronectin, a potent chemotactic factor for fibroblasts, has also been 
reported in human bronchial epithelial cells (Marini et al. 1996). Sen and co-workers have 
demonstrated that ET-1 acts on alveolar type II cells and releases surfactant phoshatadylcholine 
(Sen et al. 1994). Markeqitz et al. (1995) have demonstrated that ET-1 acts on alveolar epithelial 
cells and releases PGE-2 and cAMP via ET-A receptors. Therefore, the distribution and 
numerous physiological functions of endothelin receptors are species and region specific. 
1.11 Role of ET-1 in the Pathogenesis of Allergic Airway Diseases 
1.11.1 ET-1 and the Pathogenesis of Human Chronic Obstructive Pulmonary Disease – In 
humans, chronic obstructive pulmonary disease (COPD) is a pulmonary disorder that is 
characterized by reduced maximal expiratory flow and slow forced emptying of the lungs; 
features that do not change markedly over several months. This limitation in airflow is only 
minimally reversible with bronchodilators. Some of the most common types of COPD are 
emphysema, chronic bronchitis, asthma, cystic fibrosis, and bronchiectasis. Typically, the 
symptoms of COPD include cough, sputum (mucus) production, shortness of breath, especially 
with exercise, wheezing and chest tightness. There is also epidemiological evidence that there is 
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an increased cardiovascular risk in patients with COPD. ET-1 plays an important role in causing 
these symptoms and effects of COPD (Roland et al. 2001). Other effects of ET-1 related to 
COPD include recruitment and activation of neutrophils and alveolar macrophages (Roland et al. 
2001). Corticosteroids are generally used to reduce the exacerbations of the COPD.  One of the 
mechanisms by which they act is by reducing the production of ET-1 from airway epithelial cells 
(Radington et al. 1997). Sputum and plasma levels of ET-1 are increased during the 
exacerbations of COPD. COPD exacerbations have been strongly related to the actions of IL-6. 
Plasma ET-1 levels are increased in chronic smoking that is a frequent cause of COPD. In 
patients with COPD, the plasma ET-1 level is not affected by acute progression of pulmonary 
hypertension and hypoxemia during exercise, and persistent hypoxemia may be associated with 
an increase in the plasma ET-1 level. In addition, the findings suggest that atrial natriuretic 
peptide (ANP) and brain natriuretic peptide (BNP) may modulate pulmonary vascular tone by 
interacting with ET-1 in these patients (Fujii et al. 1999). One of the important and potentially 
serious complications of COPD is pulmonary vascular tension that also includes pulmonary 
hypertension. There are several reports describing an increase in plasma ET-1 levels in patients 
with pulmonary hypertension, with a correlation between levels and disease severity evident in 
some studies (Allen et al. 1993). Abnormalities in ET-1 pulmonary metabolism have been 
reported in patients with pulmonary hypertension, asthma and chronic obstructive pulmonary 
disease (COPD). BAL ET-1 levels are not elevated in COPD patients. This is the major 
difference between human COPD and asthma. Also, arterial ET-1 levels in stable COPD patients 
were found to be significantly greater than in patients with asthma (Nikolaou et al. 2003).  
Smoking is not associated with an induction of ET release in BAL (Reichenberger et al. 2001). 
Plasma ET-1 levels in COPD patients were similar during exacerbation and recovery and were 
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not significantly different from those in healthy subjects. Measurement of 24-hr urinary 
excretion of ET-1 showed that it is increased in COPD patients during acute exacerbation; it 
decreased during recovery, but remained elevated when compared to normal subjects. A negative 
correlation was found between arterial oxygen pressure and ET-1 excretion; no correlation was 
found between plasma and urinary ET-1 values. Hence, COPD patients excrete higher amounts 
of ET-1 compared with healthy subjects. Urinary ET-1 values are further increased during acute 
exacerbation of the disease (Sofia et al. 1994). Smokers have impaired ET-1 mediated 
vasodilatation that correlates with bronchial hyperresponsiveness and may contribute to 
pulmonary hypertension. It was shown that the responsiveness of pulmonary arterial smooth 
muscle to dilator and constrictor agents is increased in patients showing reversibility of airway 
constriction. Thus, hyperresponsiveness of airway smooth muscle may be associated with a 
similar phenomenon in the surrounding vascular smooth muscle (Cases et al. 1996).   
1.11.2 Role of ET-1 in the Pathogenesis of Asthma – Asthma is a chronic inflammatory airway 
disease characterized by airway obstruction, airway inflammation and bronchial 
hyperresponsiveness or bronchoconstriction. These symptoms are a result of airway smooth 
muscle contraction, mucus hypersecretion, and epithelial damage (contributing to mucus plug 
formation), microvascular leakage, the influx of inflammatory cells, edema, and airway 
thickening. Chronic inflammation in asthmatic airways leads to pathophysiologic changes in the 
structure of tissues, a process often referred to as airway remodeling. Such changes include 
thickening of the smooth muscles in the airway wall, which may influence airway 
responsiveness. Other structural changes that may affect airway function include disruption of 
the bronchial epithelium, subepithelial fibrosis, and goblet cell hyperplasia together with 
increased mucus accumulation in the airways (Salmon et al. 2000). ET-1 has important roles in 
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all of these symptoms. Increased levels of ET-1 in BALF, bronchial biopsies, and peripheral 
blood and alveolar macrophages in asthmatic patients confirm this finding (Radington et al. 
1995, Springall et al. 1991). This increase is due to increased local production of ET-1 from 
epithelial cells in the airways in asthmatic individuals. ET-1 causes immediate 
bronchoconstriciton in asthma (Radington et al. 1995, Chalmers et al., 1997). ET-1 in asthmatic 
subjects also stimulates mucus secretion, airway edema through microvascular leakage, smooth 
muscle mitogenesis, and also bronchial hyperresponsiveness. The expression of ET-1 is 
increased in the vascular endothelial cell of asthmatic patients. In allergic sheep, it has been 
demonstrated that aerosolized ET-1 causes bronchoconstriction, in part, by stimulation of ET-A 
receptors. ET-1 is released in the airways after antigen challenge, and this peptide contributes to 
the severity of the allergic responses, by increasing airway smooth muscle responsiveness 
(Noguchi et al. 1995). ET-1 inhalation is not associated with a late bronchoconstrictor response. 
Inhaled ET-1 does not appear to stimulate an acute inflammatory response in asthma as assessed 
by differential cell count, TNF-α, IL-1β and albumin concentrations in induced sputum 
(Chalmers 1999). In asthma, ET-1 enhances vascular permeability by mediating and/or 
modulating the secondary release of TXA-2 (Sirois et al. 1992). The bronchial epithelial cells of 
all the asthmatic patients expresses preproendothelin-1 mRNA, as assessed by in situ 
hybridization, and released high amounts of mature and biologically active ET-1. Addition of 
corticosteroids results in decreased release of ET-1 from cultured asthmatic bronchial epithelial 
cells (Vittori et al. 1992). Inhibition of ET-A or combined ET-A and ET-B receptors additionally 
leads to decreased airway inflammation in antigen challenged animals, suggesting that the 
proinflammatory effects of ET-1 in the airway are mediated mainly by ET-A receptors (Fujitani 
et al. 1997). However, most of the bronchoconstriction elicited by ET-1 in asthmatic individuals 
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is through ET-B receptors (Reichenberger et al. 2001). It was shown that the plasma 
concentrations and production from cultured mononuclear sites from asthmatic children are 
significantly greater compared with healthy children (Chen et al. 1995). Adult asthmatics have 
normal levels between attacks, but during acute attacks serum ET-1 levels are increased and 
correlate inversely with airflow measurements and decrease with treatment (with steroids, beta-
adrenergic agonists or phosphodiesterase inhibitors)(Aoki et al. 1994). ET-1 in asthmatics is 
similarly increased to concentrations that cause bronchoconstriction and inversely correlates with 
forced expiratory volume (Sofia et al. 1993). Patients with asthma also have been shown to have 
increased amounts of immunoreactive endothelin in BALF compared with normal control 
subjects or subjects with chronic bronchitis in absence of any significant alteration in the levels 
of circulating ET-1. Treatment of asthmatic patients with oral corticosteroids and inhaled beta-
agonists for 15 days resulted in improvement of airflow obstruction and in more than 3-fold 
reduction in the contents of ET-1 in lavage fluid. All these findings indicate that ET-1 
contributes significantly to the pathogenesis of airflow obstruction in asthma (Mattoli et al. 
1991). ET-1 and ET-3 are found in equal amounts in BAL fluid as well as in cultured epithelial 
cells from asthmatics (Fagan et al. 2001). ET-1 plays a role in the overnight worsening of asthma 
and perhaps is more tightly tissue bound, resulting in lower levels of BAL fluid (Kraft et al. 
1994). 
1.11.3 Role of ET-1 in the Pathogenesis of Equine Recurrent Airway Obstruction (RAO) –          
To date  very few studies have been conducted regarding the role of ET-1 in the pathogenesis of 
equine RAO. Benamou and co-workers have performed a study to investigate the effect of ET-1 
on smooth muscle from isolated equine pulmonary artery and bronchus (Benamou et al. 2003). 
In this study, they also investigated the roles of ET-A and ET-B receptors in ET-1 mediated 
 41
contraction of these tissues. For this purpose, the force generation of ring segments from 
pulmonary arteries or third-generation airways was studied in an organ bath at 37oC in response 
to exogenous ET-1 and selective ET-A or ET-B receptor antagonists. They found that ET-1 
produces concentration-dependent contractions of the equine pulmonary artery and bronchus.  
They also reported that ET-1 potency was 25 times greater in equine pulmonary artery than in 
equine bronchus. They also found that in pulmonary artery, ET-1 induced contractions were 
significantly inhibited by the ET-A receptor antagonist, but not by the ETB antagonist. In 
bronchus, dose-response curves to ET-1 were shifted to the right by an ET-A antagonist, but not 
by an ET-B antagonist. In the presence of both antagonists, the dose-response curve to ET-1 was 
shifted to the right by 4.5-fold. They concluded that ET-1 is a potent spasmogen of equine third 
generation pulmonary artery and bronchus, and that contractions are mediated via ET-A 
receptors in the former and both ET-A and ET-B receptors in the latter.  
           In another study performed by the same authors, the levels of ET-1 in systemic blood, as 
well as in BALF from horses with RAO were investigated (Benamou et al. 1998). They also 
studied how these values might correlate with those of lung function tests and pulmonary artery 
pressure. Five horses with RAO were evaluated both in remission and in crisis and compared to 
five control horses. They demonstrated that the RAO horses had significantly greater systemic 
ET-1 levels than control horses. They also found that the RAO-affected horses had a negative 
arteriovenous ET-1 difference that may correspond to a net uptake of ET-1 in the lung. Another 
important finding in this study was that the RAO horses in crisis had increased amounts of 
immunoreactive ET-1 in BALF when compared to normal horses. Additionally, they also 
showed that the reduction in lung function seen in RAO horses in crisis was significantly 
correlated with lower epithelial lining fluid ET-1 levels. The same authors have examined for the 
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possible variations in ET-1 concentrations occurring during exercise in COPD-affected horses 
(Benamou et al. 1999). They compared the effects of intense treadmill exercise on the recovery 
of ET-1 in the BALF as well as in arterial and venous blood, in a group of 5 healthy horses and a 
group of 5 COPD-affected horses studied alternately in remission and while symptomatic. They 
also investigated the possible correlations between ET-1 levels and pulmonary function tests 
during the study. They found that while exercise did not affect the ET-1 levels recovered in 
BALF among controls, it caused a significant increase among symptomatic COPD-affected 
horses. During remission, wide variations of ET-1 levels among horses at rest and during 
exercise made the interpretation difficult. Furthermore, no correlation could be found between 
exercise-induced changes in ET-1 concentrations and pulmonary function tests or changes in 
arterial oxygen tension with exercise. They concluded that exercise appears to affect the release 
of ET-1 by the airways in COPD-affected horses, in contrast to healthy horses. The findings of 
all three studies conducted by Benamou et al, suggest that ET-1 might play a pivotal role in the 
pathogenesis of equine RAO.  
1.12 Epithelium and Airway Allergic Diseases 
1.12.1 Functions of Epithelium – The epithelium has many important physiological functions in 
the lungs. It basically acts as a barrier to airborne irritants. The cilia present on the luminal side 
of the epithelial cells beat rhythmically to push the irritants and the mucus present in the airways. 
Epithelium mediates a vital role in the modulation of airway tone. It releases many airway 
smooth muscle relaxing factors such as epithelium-derived relaxing factor (EpDRF) and NO. 
Similarly, in horses it has been shown that epithelium is a source of inhibitory prostanoids such 
as PGE-2, which inhibits smooth muscle contraction and prevents bronchospasm (Gray et al. 
1992).  In addition, airway epithelium is metabolically active, since there are several enzymes 
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such as acetylcholinesterase, histaminase and peptidases, which can inactivate contractile 
agonists. Furthermore, the presence of receptors for inflammatory mediators, neurotransmitters 
and cytokines and the significant influence exerted on isolated airway smooth muscles highlights 
that the epithelium is more than a simple barrier. The loss of such a barrier, allowing an 
increased access of noxious chemicals and high molecular weight allergens, together with the 
exposure and subsequent up-regulated activation of sensory nerves, may contribute to the state of 
airway hyperresponsiveness which usually accompanies chronic obstructive lung diseases. 
1.12.2 Role of Epithelium in Airway Allergic Diseases – Epithelial disruption is a feature of 
the inflammation associated with asthma (Laitinen et al. 1993, Laitinen et al. 1985). In a study 
done by Candenas and co-workers to investigate the effect of epithelial removal and 
enkephalinase inhibition on bronchoconstrictor responses induced by ET-1, it was demonstrated 
that the removal of the epithelium significantly enhanced the two stages of the contractile 
responses to the three endothelins (Candenas et al. 1992).  The first stage was observed with the 
low concentrations of agonists and corresponded to low intrinsic activity and the second phase 
was with high concentration which corresponded with high intrinsic activity. Epithelium removal 
also abolished the differences in potency efficacy that were observed between ET-1, ET-2 and 
ET-3 when the epithelium was present. Phosphoramidon, an enkephalinase inhibitor, was as 
potent as epithelium removal in enhancing the contractile responses to these agonists at low 
concentrations. However, with high concentrations of endothelins, phosphoramidon was less 
potent than epithelium removal in enhancing the contractile responses. In epithelium-denuded 
strips, preincubation with phosphoramidon did not further increase the maximal contractions 
induced by/or the potencies of ET-1, ET-2 or ET-3. After epithelium removal, responses to low 
doses of endothelins were attenuated by nicardipine, a calcium channel blocker, whereas 
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responses to high doses of the endothelins were not affected, as was also observed when the 
epithelium was present (Barnes PJ. 1994, Candenas et al. 1992). Thus epithelial damage 
contributes significantly to the enhanced contractile response of the bronchi to endothelins. Intact 
epithelium in normal subjects forms a physical barrier to ET-1 coming into contact with 
submucosal target cells or increases in clearance and metabolism of ET-1, either by binding and 
internalization of ET-1 by ET-B receptors (Fukuroda et al. 1994) or by enzymatic degradation. In 
humans, it has been shown that ET-1 decreases bronchial epithelial cell migration, causes 
inhibition of repair of epithelium and it also enhances remodeling (Dosanjh and Zuraw 2003) 
There is also evidence in human non-asthmatic tissue that ET-1 can act on ET-A receptors in 
bronchial epithelium causing release of NO and other relaxant factors, which could attenuate 
bronchoconstrictor effects of ET-1 in normal airways (Chalmers et al. 1997). It has also been 
demonstrated in vitro that ET-1 may interact with other mediators implicated in asthma, with 
potentiation of its activity, including prostaglandins PGD-2 and PGF-2α, LTD-4, and 
angiotensin II. 
 In vitro studies conducted on equine airway epithelium derived from healthy and COPD-
affected horses have shown that epithelial strips from COPD-affected horses tended to produce 
smaller amounts of PGE-2, an inhibitory prostanoid,  than did the strips from control horses 
(Gray et al. 1992). This finding suggests that the defective production of PGE-2 is one of the 
factors responsible for the pathogenesis of equine COPD. Moreover, in isolated bronchi from 
horses with heaves the inhibitory function of the prostanoids is reduced (Yu et al. 1994). All 
these findings suggest that epithelial alteration could play an important role in the pathogenesis 
of equine RAO.          
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1.13 Goals of this Dissertation 
           In our preliminary in vitro pharmacological studies, we found that when equi-molar 
concentrations of ET-1 are applied to the bronchial tissues of healthy and SPAOPD-affected 
horses, ET-1 caused a concentration-dependent contraction of these tissues in both groups of 
horses; however, the response was significantly greater in the diseased horses than the healthy 
horses. Owing to these findings and extremely important roles played by ET-1 and its receptors 
in the pathogenesis of many airway allergic diseases in various species, we wanted to investigate 
if there are any alterations in the affinity, expression, density and distribution of ET receptors in 
the lungs of SPAOPD-affected horses. In addition, we also studied the effect of epithelial 
denudation combined with ET-receptor antagonism, on ET-1 mediated airway smooth muscle 
constriction.   
           As exaggerated bronchoconstriction is an important feature of obstructive pulmonary 
diseases, we wanted to investigate if there is any alteration in the affinity of ET-receptors in the 
bronchial smooth muscles of SPAOPD-affected horses. For that purpose we employed 
pharmacological studies to determine and compare the pharmacological affinities of ET-A and 
ET-B receptors by using specific antagonists in both healthy and SPAOPD-affected horses. In 
these studies we determined the pA2 values of each ET-receptor antagonist in healthy and 
SPAOPD-affected horses. The pA2 value is a statistical constant which is calculated to assess the 
pharmacological affinity of the antagonist for its receptor. We also conducted 
immunohistochemical studies on bronchial smooth muscles and bronchial epithelial cells to 
examine for any changes in the expression of ET-A and/or ET-B receptors. 
            Most important histopathological findings in equine RAO can be observed in peripheral 
lungs which include bronchioles, capillaries, alveolar septa and inflammatory cells in the alveoli. 
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In fact, the principal lesion in COPD and SPAOPD-affected horses is bronchiolitis (Ronbinson et 
al. 1996 and Costa et al. 2000). Hence, we wanted to investigate for the presence of alteration in 
ET receptor expression in peripheral lungs. Previous studies have revealed that 
immunohistochemical, molecular biological and western blotting techniques are some of the 
most reliable and accurate techniques to characterize and compare the expression of ET receptors 
in lungs. For example, studies which employed immunohistochemical techniques to study the 
changes in ET receptor expression in developing human perinatal lung, rat pulmonary veins 
subjected to hypoxia, rat and guinea pig airway nerves, human scleroderma associated fibrotic 
lung disease, and rat lungs affected with pulmonary hypertension, have revealed that 
immunochemistry is a very reliable and dependable technique to characterize ET receptors in 
lungs of various species (Yorikane et al. 1993, Abraham et al. 1997, Fernandes et al. 1998, 
Takahashi et al. 2001 and Levy et al. 2005). 
           Similarly, studies that employed western blotting to characterize the presence of ET 
receptors in human lungs affected with pulmonary edema, in rat lungs affected with post-
obstructive pulmonary vasculopathy and in the bronchial smooth muscles of rats have revealed 
that western blotting is a very useful technique to detect the presence of ET-receptors in the 
lungs of various mammalian species (Chiba et al. 2005, Kim et al. 2002 and Carpenter et al. 
2003). Also, studies employing RT-PCR to detect the presence of ET receptor expression in the 
airway smooth muscles of allergic lungs, in the bronchial epithelium and lung cancer of humans, 
in the bronchial biopsies of patients affected with asthma and COPD have shown that this 
technique is highly accurate to determine and compare the expression of ET receptors (Moller et 
al. 1999, Ahmed et al. 2000 and Granstrom et al. 2004). Hence, to investigate the presence of 
alteration in the ET receptor expression in the peripheral lungs of SPAOPD affected horses, we 
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employed immunohistochemical, molecular biological and western blotting studies to determine 
and compare the expression of ET-A and ET-B receptors in the peripheral lungs of healthy and 
SPAOPD-affected horses. 
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CHAPTER 2. IN VITRO  EFFECT OF RECEPTOR ANTAGONISM AND EPITHELIAL 
DENUDATION ON THE ET-1 INDUCED CONCENTRATION-DEPENDENT 



























               Summer pasture-associated obstructive pulmonary disease (SPAOPD) of horses is a 
form of recurrent airway obstruction (RAO) that commonly occurs in subtropical regions of the 
US from late summer to early fall. The susceptible horses develop clinical exacerbations when 
they are allowed to graze lush pastures during these seasons (Beadle 1983, Seahorn and Beadle 
1994, Robinson 2001). The RAO is induced by allergic reactions and characterized by 
respiratory distress, airway inflammation, airway hyperreactivity, and airway remodeling during 
the progression of the disease (Robinson 2001, Naylor et al. 1992).  Airway hyperreactivity is a 
condition characterized by hypersensitivity and hyperresponsiveness to various stimuli.  During 
periods of acute exacerbations of RAO, horses develop airway hyperreactivity in response to the 
inflammatory mediators released into the airways, leading to severe bronchoconstriction (Yu et 
al. 1994, Benamou et al. 1998).  These mediators can also induce increased vascular 
permeability, mucus hypersecretion and airway epithelial disruption (Robinson 2001). 
Endothelin-1 (ET-1) is a 21 amino acid peptide and has been implicated in airway 
hyperreactive diseases such as human asthma, human COPD and equine RAO (Benamou et al. 
1998, Mattoli et al. 1991).  In the lungs, ET-1 is synthesized by various types of cells, including 
pulmonary vascular endothelium, airway smooth muscle and airway epithelium (Rubanyi and 
Polokoff 1994).  ET-1 exerts its effects by acting through two types of receptors, namely ET-A 
and ET-B receptors (Rubanyi and Polokoff 1994).  
 Benamou et al., have shown that ET-1 induces potent contraction of equine third 
generation bronchial smooth muscle by acting through both ET-A and ET-B receptors (Benamou 
et al. 2003). The same investigators have reported that ET-1 levels in the systemic circulation 
and in the bronchoalveolar lavage fluid (BALF) of RAO horses are significantly greater than 
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those of clinically normal horses (Benamou et al. 1998).  The findings of these studies suggest 
that ET-1 might play an important inflammatory mediator role in equine airway hyperreactive 
diseases.   
  Our pilot in vitro pharmacological studies showed that when bronchial rings from 
SPAOPD-affected and unaffected horses were applied with equi-molar concentrations of ET-1, 
the contractile responsiveness of the rings from the affected horses was significantly greater than 
that of unaffected horses.  This prompted us to investigate the possibility of alterations in the 
affinity of ET receptors to ET-1 in the airways of SPAOPD-affected horses.   
            Epithelial disruption is a feature of the inflammation associated with airway allergic 
diseases such as asthma (Laitinen et al. 1993, Laitinen et al. 1985). It has been demonstrated that 
the removal of the epithelium significantly enhances the contractile responses of bronchi to 
endothelins (Candenas et al. 1992). This is because the intact epithelium in normal subjects 
forms a physical barrier to ET-1 coming into contact with submucosal target cells or increases in 
clearance and metabolism of ET-1, either by binding and internalization of ET-1 by ET-B 
receptors or by enzymatic degradation (Fukuroda et al. 1994). There is also evidence in human 
non-asthmatic tissue that ET-1 can act on ET-A receptors in bronchial epithelium causing release 
of NO and other relaxant factors which could attenuate bronchoconstrictor effects of ET-1 in 
normal airways (Chalmers et al. 1997). In vitro studies carried out on equine airway epithelium 
derived from healthy and COPD-affected horses have shown that epithelial strips from COPD-
affected horses tended to release smaller amounts of PGE2, an inhibitory prostanoid,  than did 
strips from control horses (Gray et al. 1992). This finding suggests that the defective production 
of PGE2 is one of the factors responsible for the pathogenesis of equine COPD. Moreover, in 
isolated bronchi from horses with heaves the inhibitory function of the prostanoids is reduced 
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(Yu et al. 1994). All these findings suggest that epithelial alteration could play an important role 
in the pathogenesis of equine RAO.    
             In this study, we hypothesized that 1) the bronchi of SPAOPD-affected horses would 
show a significantly greater contractile response to ET-1 when compared to unaffected horses, 
and this exaggerated responsiveness could be due to alteration in the pharmacological affinity of 
ET receptors to ET-1, and 2) the bronchi in both groups of horses would respond greater when 
epithelium is removed than with intact epithelium.  Therefore, the objectives of this study were  
1) to determine and compare the pharmacological responses of bronchi from SPAOPD-affected 
and unaffected horses to graded concentrations of ET-1, 2) to detect and compare the alterations 
in the bronchial smooth muscle ET-A and ET-B receptor affinities, by using receptor antagonists 
and their pA2 values, a statistical constant that indicates receptor affinity, (Schild 1947) and 3) to 
determine and compare the pharmacological responses of bronchi with intact epithelium to those 
with epithelium removed, in both groups of horses.    
2.2 Materials and Methods 
2.2.1 Horses – This study was approved by the Institutional Animal Care and Use Committee of 
Louisiana State University. All horses were procured by donation. All SPAOPD-affected horses 
had a history of signs of obstructive pulmonary disease after they were exposed to pasture in the 
summer (Seahorn and Beadle 1993). Eight clinically healthy (control or unaffected) horses, 10 to 
20 years old (mean ± SD, 15.5 ± 4.9 years) and eight SPAOPD-affected horses, 10 to 20 years 
old (mean ± SD, 14.3 ± 3.9 years) were included.  
2.2.2 Clinical Evaluation – On the day of clinical evaluation, the general demeanor and 
respiratory behavior of the horse were observed. Rectal temperature (oF), heart rate (beats/min), 
respiratory rate (breaths/min), nostril flare and abdominal lift were recorded. In addition, the 
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respiratory sounds were assessed by auscultation. Finally, the clinical score (CS) and change in 
transpleural pressures (∆ Ppl) were determined.  
2.2.3 Clinical Scoring (CS) – Clinical scores were determined by use of the following algorithm 
(Seahorn and Beadle 1997). 
                  CS = (Medial nostril flare + Lateral nostril flare)/2 + Abdominal lift 
Each of the variables in the above algorithm was scored from 0 to 4. A score of “0” indicates that 
the nostril had little movement and the ventral flank showed little or no movement. A score of 
“4” indicates that the nostril remained maximally flared throughout the respiratory cycle and the 
abdominal lift resulted in a “heave line” that extended cranially to the 5th intercostal space.  
Thus the maximum clinical score is “8”. 
2.2.4 Change in Transpleural Pressure (∆Ppl) – The change in transpleural pressure (∆Ppl) 
was measured indirectly by using an esophageal balloona secured over the end of a catheter 
connected to a pressure transducer interfaced with a polygraphb. A 10-cm long, 3.5 cm 
circumference balloon was placed over the end of a 2-m long, 2-mm diameter canula. The 
balloon was inserted through a lubricated nasogastric tube that was passed into the rostral 
esophagus. Once the balloon was located between the heart and diaphragm, the nasogastric tube 
was removed. The balloon was inflated with 1.5 ml of water and measurements were recorded 
for one minute. Changes in the esophageal pressure (peak inspiratory minus peak expiratory 
pressures) during tidal breathing reflect the change in transpleural pressure.  
2.2.5 Grouping – For inclusion in the study, all horses must have had normal reference values of 
rectal temperature (~38.6 oC), heart rate (~30 to 40 per minute), respiratory rate (~10 to 20 per 
minute) and thoracic auscultation. In addition, none of the horses included in this study had 
received any medication at least 7 days prior to clinical evaluation. To be included in the 
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SPAOPD-affected group, in addition to the history of SPAOPD, the horses must have had a CS ≥ 
5.0 and a ∆Ppl ≥ 15.0 cm of H2O. Similarly, to be included in the clinically healthy group, the 
horses must have had a CS ≤ 4.0 and ∆Ppl ≤ 10.0 cm of H2O. 
2.2.6 In vitro Concentration-Response Studies – The next day after evaluation and grouping, 
horses were humanely euthanatized using an intravenous overdose (90 mg/kg) of sodium 
pentobarbitalc. Gross post-mortem evaluation of the lungs was conducted before removing them 
from the thoracic cavity. Ten bronchial rings, each measuring approximately 3-4 mm in 
diameter, were prepared from right diaphragmatic lung lobe in the region of fourth to seventh 
generation bronchi, a region that has high airflow resistance under normal conditions (Venugopal 
et al. 2001).  This region is also preferred for its ease to identify and maintain the consistency of 
location of airways in different animals (Venugopal et al. 2001).  Immediately after preparing the 
bronchial rings, each ring was mounted separately in an organ bath containing 95% oxygenated 
Tyrode’s solution at 37oC.  Each ring was fixed on one side to the floor of the bath and the other 
side was attached by a silk thread to a force transducerd interfaced with the polygraph.  An initial 
tension of 2 gm was applied to each ring to mimic the airway tone observed under in vivo 
conditions (Venugopal et al. 2001). Out of the ten bronchial rings, four were used for the ET-A 
receptor antagonist (BQ-123) e study, another four were used for the ET-B receptor antagonist 
(IRL-1038) e study and the remaining two rings were used as controls i.e. one ring with intact 
epithelium and the other ring with denuded epithelium, both receiving no antagonist.  One of the 
4 rings in each receptor antagonist study was manually denuded of epithelium and incubated 
with 10-5M concentration of the antagonist; the other three rings were incubated with one of 
three concentrations of the antagonists (10-9 M, 10-7M and 10-5M) after the first wash.  The 
bronchial epithelium was mechanically removed by very gentle abrasion of its lumen with small 
 69
forceps. Effectiveness of epithelium removal was evaluated by subjecting extra rings (i.e. these 
rings were not used in the experiment) to the same procedure and then hematoxylin and eosin 
staining. The rings were allowed to equilibrate for 45 minutes and the bath fluid was gently 
replaced with fresh, warm Tyrode’s solution at 15-minute intervals. After each solution change, 
the tension was reapplied to maintain 2 gm except following the last solution change.  
Antagonists were also added after each wash including the final wash.  
After completion of the equilibration period, cumulative concentration-response (CR) 
relationships were determined by adding graded concentrations of ET-1 (ranging from 10-8.5 to 
10-6 M) to each bath, at 3-minute-intervals (Van Rossum 1963, Venugopal et al. 2001).  The 
maximum concentration of ET-1 was limited to 10-6 M due to the high-cost involved.  The 
maximal contraction of the rings was determined by adding 10-3 M of carbachol.  Thus, the 
response induced by the carbachol was considered as 100% and was used to calculate the 
percentage response induced by each concentration of ET-1.  The responses of the rings on a 
weight basis (mg of tension/mg of dry weight) were also calculated to compare with the method 
used in percentage response of maximal carbachol response.  Since there was no significant 
difference in these two methods, EC50 values (the effective concentration of ET-1 to produce 
50% of the maximal contraction) were determined from the cumulative CR curves.  These EC50 
values were used for calculation of the pA2 values. 
2.2.7 Determination of the pA2 Values – A slightly modified linear regression analysis method 
known as Schild plot was used to determine pA2 values (Schild 1947).  The pA2 value is a 
statistical measure of the pharmacological affinity of a competitive antagonist for its receptor.  It 
is defined as the negative logarithm of the molar concentration of an antagonist that will reduce 
the effect of twice the dose of an agonist to that of a single dose (Schild 1947, Arunlakshana and 
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Schild 1950).  In general, the greater the pA2 value, the greater is the affinity of the antagonist 
for the receptor.  
The pA2 value was determined by using the CR curves of ET-1 in the absence (control 
ring) and presence of the antagonist.  The CR curve of ET-1 is shifted in the presence of the 
antagonist and this shift is reflected in the EC50 value of ET-1.  After determining the EC50 
values for ET-1 in each of these curves (control rings as well as those treated with antagonists), 
the next step was to determine concentration ratios for each antagonist.  The concentration ratio 
is the ratio of the EC50 value of the control curve (without the antagonist) to the EC50 value of 
the ET-1 in the presence of the antagonists.  Three concentrations of the antagonist were used in 
the experimental design.  Therefore, three concentration ratios for each antagonist were obtained 
in each receptor study.  Finally, pA2 values were determined by plotting the log (concentration 
ratio – 1) on the y-axis against the log molar concentration of the antagonist on the x-axis.  The 
slope was extended to intersect the point on the x-axis that corresponds to the molar 
concentration of the antagonist.  This point is zero on the y-axis.  Because the y-axis is plotted as 
a value of log (concentration ratio – 1), the value of zero on the y-axis represents an actual 
concentration ratio of two.  The negative logarithm of the molar concentration at which the line 
intersects the x-axis is the pA2 value (Schild 1947, Venugopal et al. 2001). 
2.2.8 Statistical Analyses – Graph pad Prism ver.4.0f was used for performing all statistical 
analyses. The CS and ∆Ppl data was analyzed and comparison between clinically healthy and 
SPAOPD-affected horses using the Mann-Whitney test. Cumulative CR relationships in 
SPAOPD-affected and unaffected horses were analyzed and compared using two-way ANOVA.  
Wherever significance was indicated, post-hoc comparisons were made using Bonferroni’s test.  
The pA2 values for ET-A and ET-B receptor antagonists in SPAOPD-affected and unaffected 
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horses were analyzed for significance by comparing their 95% confidence intervals, which were 
determined using a “t” distribution with n-2 degrees of freedom. The statistical significance was 
set at a p < 0.05 for all tests. 
2.3. Results  
2.3.1 Clinical Evaluation – The mean values of heart rate, respiratory rate and rectal 
temperature for SPAOPD-affected and unaffected horses are given in Table 2.1. All horses were 
in relatively good body condition and had a normal appetite and demeanor. All SPAOPD-
affected horses had respiratory wheezes on auscultation, nostril flaring, increased abdominal lift 
and cough. Few SPAOPD-affected horses showed a marked ‘heave’ line extending along the 
abdominal wall. The CS (median 5.5; range, 5.0 to 7.0) of SPAOPD-affected horses was 
significantly greater than that of clinically healthy horses (median 2.0; range, 1.0 to 3.5; Table 
2.1).  Similarly, the ∆Ppl of SPAOPD-affected horses (median 25.0 cm of H2O; range 20 to 32) 
was significantly greater than that of clinically healthy horses (median 7.0 cm of H2O; range, 4.0 
to 9.0).   
    
Table 2.1 – Median and range values for signalment, clinical signs, clinical score and ∆Ppl for 
clinically healthy and SPAOPD-affected horses. * Indicates significant (P ≤ 0.05) difference 
between clinically healthy and SPAOPD-affected horses. a,b Values with different superscript 
letters differ significantly (P ≤ 0.05). HR = heart rate, RR= respiratory rate, CS = clinical score, 
∆Ppl = transpleural pressure, y = years, F = Fahrenheit, bpm = beats per minute, rpm = 
respirations per minute. 
                                                  
       Clinically healthy                         SPAOPD-affected 
Variable Median Range Median Range 
Age (y) 15.5 10-20 14.3 10-20 
Temp (F) 100.4 100.0-102.0 100.2 98.6-102.0 
HR (bpm) 39 34-63 43 31-68 
RR (rpm) 22 17-24 23 18-37 
CS* 2.0 1.0-3.5 5.50 5.0-7.0 




2.3.2 Gross Post-Mortem Evaluation of Lungs – The lungs of all SPAOPD-affected horses 
were over-inflated and orange-pink in color. In these horses, after the thoracic cavity was 
opened, the lungs did not collapse. A tough texture was observed in some regions of the lungs. 
Non-uniformly distributed, pale, fibrotic patches were observed on the surface of the lungs of 
many affected horses. In addition, the surface of the lungs of some affected horses had 
indentions or impressions caused by pressure from the ribs. Mucus plugs were frequently 
observed in the bronchi; however, this observation was not uniform throughout the lung fields. 
           Healthy horses had lungs which were of normal size, texture and pale pink in color. 
Neither fibrotic patches nor rib impressions were observed on the lung surface. The lungs 
collapsed immediately and completely after opening the thoracic cavity. Bronchial mucus plugs 
were noticed on only a few occasions. 
2.3.3 Responses of Control Rings with Intact Epithelium – Graded concentrations of ET-1 
caused a concentration-dependent contraction of control bronchial rings in both groups of horses.  
The contraction caused by ET-1 on control rings obtained from SPAOPD-affected horses was 
significantly greater than that of unaffected horses (Fig 2.1).  The significance was evident at 10-
7M to 10-6M concentrations of ET-1.  
2.3.4 Responses of Rings of Healthy Horses in the Presence of ET-A Antagonist – The EC50 
values of the concentration-dependent contractions elicited by ET-1 on bronchial rings collected 
from unaffected horses in the presence of ET-A receptor antagonist bq-123 at 10-9 M, 10-7M and 
10-5M concentrations are illustrated in Figure 2.2. In general, the potency of a drug is indirectly 
proportional to the EC50 value; thus, the lower the EC50 value, the greater is the potency of the 
drug or greater the sensitivity of the target tissues to the drug. In these horses, blockade of ET-A 
receptors (i.e. ET-B receptors were open) resulted in an increase in the response to ET-1 in 
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Figure 2.1 − ET-1 mediated concentration-dependent responses of the control rings with intact 
epithelium in healthy and SPAOPD-affected horses. * indicates a statistically significant 
difference in the control bronchial responses between healthy and SPAOPD-affected horses. 
 
antagonist concentration-dependent manner when compared to control rings. In other words, the 
greater the concentration of the ET-A antagonist, the greater the contraction elicited by ET-1. 
Statistical significance was evident at 10-5M concentrations of the antagonist.            
2.3.5 Responses of  Rings of Healthy Horses in the Presence of ET-B Antagonist – In healthy 
horses, when ET-B receptors were blocked (i.e. ET-A receptors were open) with ET-B receptor 
antagonist IRL-1038, the response to ET-1 was decreased in antagonist concentration-dependent 



















Figure 2.2 – Effect of ET-A receptor antagonism (BQ-123) on ET-1 induced responses of the 
bronchial rings from healthy horses. * indicates a statistically significant difference between the 
responses of bronchial rings supplied with 10-5 M concentration of ET-A receptor antagonist and 
control rings. 
 
ET-B receptors were blocked (Figure 2.3). Therefore, classical competitive antagonism took 
place in this case. However, statistical significance was evident only at 10-5M concentration of 
the antagonist.  
2.3.6 Responses of Rings of SPAOPD Horses in the Presence of ET-A Antagonist – In 
SPAOPD-affected horses, when ET-A receptors were blocked (i.e. ET-B receptors open), the 
response of the rings to ET-1 was increased similar to that of healthy horses. In other words, the 
EC50 values decreased when the ET-A receptors were blocked (figure 2.4). This increase was 
statistically significant at 10-7M and 10-5M concentrations of the antagonist.  
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Figure 2.3 − Effect of ET-B receptor antagonism on the ET-1 induced responses of the bronchial 
rings from healthy horses. * indicates a statistically significant difference between the responses 
elicited by the bronchial rings supplied with 10-5 M concentration of ET-B receptor antagonist 




















 Figure 2.4 − Effect of ET-A receptor antagonism on the responses induced by ET-1 on the 
bronchial rings from SPAOPD-affected horses. * indicates a statistically significant difference 
between the responses of bronchial rings supplied with 10-5 M concentration of ET-A receptor 
















Figure 2.5 − Effect of ET-B receptor antagonism on the ET-1 induced responses of bronchial 
rings of SPAOPD-affected horses. * indicates a statistically significant difference between the 
responses of bronchial rings supplied with 10-7 and 10-5 M concentration of ET-B  receptor 
antagonist, and control rings.  
 
2.3.7 Responses of Rings of SPAOPD Horses in the Presence of ET-B Antagonist – Similar 
to the healthy horses, when ET-B receptors were blocked (i.e. ET-A receptors were open) in 
bronchial rings of SPAOPD-affected horses, the response to ET-1 decreased in antagonist 
concentration-dependent manner when compared to the control rings. In other words the EC50 
values increased when the ET-B receptors were blocked (Figure 2.5). Therefore, classical 
competitive antagonism also took place in this case. Statistical significance was evident at    10-
7M and 10-5M concentrations of the antagonist. 
2.3.8 pA2 Values – In both groups of horses, the pA2 values for the ET-A antagonist could not 
be determined because of shifting of the curve towards the left when the ET-A receptors were 
* *
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blocked. Because of this leftward shift, the dose ratio could not be calculated since the logarithm 
of a negative number could not be determined. However, the pA2 values for the ET-B antagonist 
could be determined in both groups of horses. This is because the curve shifted toward the right 
when the ET-B receptors were blocked. The pA2 values for ET-B antagonist were 3.08 + 2.91 
and 9.98 + 3.36, for unaffected and SPAOPD-affected horses, respectively (Figures 2.6 and 2.7).   

















 Figure 2.6 − Schild plot to determine the pA2 value of bronchial ET-B receptors in healthy 
horses 
 
The ET-B receptors showed less affinity to ET-1 to induce a contractile response in unaffected 
horses (3.08 + 2.91), whereas in SPAOPD-affected horses the affinity was increased 
significantly (9.98 + 3.36).  The pA2 value for the ET-B receptor antagonist in SPAOPD-affected 
horses was significantly greater (P=0.01) than unaffected horses.   
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2.3.9 Effect of Epithelium Removal on ET-1 Induced Bronchoconstriction – Removal of 
epithelium significantly increased the ET-1 induced responses of bronchial rings in both groups 
of horses. However, this significance was greater in healthy horses than in SPAOPD-affected 
horses.  


















 Figure 2.7 − Schild plot to determine the pA2 value of bronchial ET-B receptors in SPAOPD-
affected horses. 
 
2.4. Discussion  
            This study revealed important findings regarding the functional role of ET-1 and its 
receptors in equine airways in health and disease.  Firstly, ET-1 causes a potent, concentration-
dependent contraction of bronchial rings of SPAOPD-affected and unaffected horses by acting 
through both ET-A and ET-B receptors.  Secondly, the bronchial rings from SPAOPD-affected 
horses show significantly greater contraction to ET-1 when compared to unaffected horses.  
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Thirdly, blockade of ET-A receptors caused an increase in the ET-1 induced responses of the 
bronchial rings in both groups of horses, suggesting a possibility of the presence of an interaction 
between these receptors.        
 














 Figure 2.8 − Effect of epithelium removal on the ET-1 induced responses of the bronchial rings                          
of healthy and SPAOPD-affected horses. * indicates statistically significant difference between 
the responses elicited by epithelium removed control bronchial rings and epithelium intact 
control bronchial rings in healthy horses. † indicates statistically significant difference between 
the responses elicited by epithelium removed control bronchial rings and epithelium intact 
control bronchial rings in SPAOPD-affected horses. 
 
Fourthly, the affinity of ET-B receptors for ET-1 increases significantly in the SPAOPD-affected 
horses when compared to unaffected horses. Finally, removal of epithelium causes a significant 
increase in the responses elicited by ET-1 in both groups of horses; however, this increase is 
significantly greater in healthy horses when compared to SPAOPD-affected horses, suggesting 




           Benamou and co-workers have demonstrated that ET-1 induces in vivo 
bronchoconstriction in equine airways by acting through both ET-A and ET-B receptors. One of 
the findings of the current study supplements those reports. In addition, we demonstrated that 
control rings from the SPAOPD-affected horses contract with significantly greater magnitude 
than those of healthy horses. This suggests that ET-1 could be an important factor in the 
generation of airway hyperresponsiveness associated with this disease. Such a role of ET-1 has 
already been demonstrated in the hyperresponsiveness associated with human asthma, human 
COPD and experimental allergic inflammation. This study is the first to demonstrate such a role 
for ET-1 in equine SPAOPD. 
           In this study, we wanted to determine and compare the pA2 values of both ET-A and ET-
B receptors in both groups of horses to evaluate the pharmacological affinities associated with 
these receptors. However, we were unable to calculate the pA2 values for ET-A receptors in both 
groups of horses. The reason is that, in order to estimate the pA2 values, we need to calculate the 
logarithm of (dose ratio-1). The dose ratio is the ratio of the EC50 of the bronchial ring to which 
an antagonist is applied to the EC50 of the control ring. The (dose ratio-1) must always be a 
positive value to determine the logarithm of this parameter. That means the EC50 of the control 
rings must always be lower than that of the rings to which antagonists are added. When 
competitive antagonism takes place, the EC50 of the control ring is always less compared with 
the rings to which antagonist is applied. In other words, the concentration-response curve 
associated with the agonist will shift toward the right when the antagonist is applied. This is 
because we need to add more agonist to displace the antagonist from the receptor on these tissues 
for them to reach the same maximal contraction. However, in the current study, when we 
blocked the ET-A receptors, ET-B receptors were activated and appeared to take over the 
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function of contraction. Furthermore, this ET-B mediated contraction (i.e. ET-A receptors are 
blocked) appeared to be more powerful than that of the control rings whereby the ET-A receptors 
were not blocked. In other words, the concentration-response curves shifted to the left when the 
ET-A blocker was added to the tissues. For this reason, the (dose ratio-1) value happened to be a 
negative number for these rings. Because we cannot calculate the logarithm of a negative value, 
the pA2 values for ET-A receptors could not be determined in either group of horses. One of the 
possible reasons for this observation could be because of the presence of an interaction between 
ET-A and ET-B receptors. Mickley and co-workers have demonstrated the presence of such 
interaction in rat isolated mesenteric arteries (Mickley et al. 1997). Similar observations have 
been obtained in rabbit pulmonary artery and human bronchi (Fukuroda et al. 1994, Fukuroda et 
al. 1996). Even though the exact mechanism of this receptor crosstalk has not been 
demonstrated, interaction at second messenger level has been suggested as a possible cause.  
Existence of allosteric interaction between these two receptors has also been demonstrated in rat 
heart (Sokolovsky 1993).    
Nevertheless, the curves shifted toward the right in both groups of horses when ET-B 
receptors were blocked. Hence we were able to determine the pA2 values for ET-B antagonists. 
These values were 3.08 + 2.91 and 9.98 + 3.36 in normal and SPAOPD-affected horses, 
respectively. In addition, the pA2 value of the ET-B antagonist in SPAOPD-affected horses was 
significantly greater than that of healthy horses. Therefore, the pharmacological affinity of 
bronchial smooth muscle ET-B receptors is significantly increased in SPAOPD-affected horses. 
As described previously in this discussion, when the ET-A receptors were blocked, the curve 
shifted toward the left in both groups of horses. However, this shift was greater in SPAOPD-
affected horses compared with that of healthy horses. In healthy horses, the significance was 
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evident only at 10-5M concentration of the antagonist. But in SPAOPD-affected horses, the 
significance was observed at 10-7M and 10-5M concentration of the antagonist. One of the 
possible reasons for the greater shift of the curve to the left in SPAOPD-affected horses could be 
due to an increased affinity of the ET-B receptors in these horses. As the affinity of ET-B 
receptors increases, a little blockade of ET-A receptors may be sufficient for the ET-B receptors 
to assume the function of bronchoconstriction. Similarly, the rightward shift of the curve when 
the ET-B receptors were blocked was significantly greater in SPAOPD-affected horses than that 
of healthy horses. The significance was evident only at 10-5M concentration of the antagonist in 
healthy horses. However, the significance was evident at 10-7M and 10-5M concentrations of the 
antagonist in SPAOPD-affected horses. That means, while a 10-7 M concentration of the 
antagonist was able to block all of the ET-B receptors in healthy horses it was unable to block 
the ET-B receptors completely in SPAOPD-affected horses because of the up-regulation of ET-B 
receptors in these horses. All of these observations suggest that ET-B receptors play an important 
role in the ET-1 induced hyperresponsiveness associated with equine RAO. 
            Another important finding of the current study was that the epithelium plays an important 
role in the regulation of bronchial tone of both healthy and SPAOPD-affected horses. Epithelium 
produces many smooth muscle relaxing agents such as NO and prostanoids. These agents 
antagonize the smooth muscle constriction elicited by agents such as ET-1. When the epithelium 
is removed, these agents will not be released and the contraction is exaggerated. This was 
observed in both groups of horses. However, this increase in the contraction of epithelium- 
denuded bronchial rings over the epithelium intact rings was much greater in healthy horses 
compared with SPAOPD-affected horses. This might either be because of the damage to the 
epithelium that occurs in the acute exacerbation of this disease or decreased production of the 
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smooth muscle relaxants by the epithelium in diseased horses. Future studies are warranted to 
determine the exact cause of this observation.    
2.5 Summary 
In summary, the present study demonstrated that the SPAOPD-affected horses show 
hyperresponsiveness to ET-1.  We also showed that this ET-1 induced hyperreactivity in 
SPAOPD-affected horses is associated with an increase in the affinity of bronchial smooth 
muscle ET-B receptors.  This study also suggests that an interaction or receptor cross-talk could 
exist between ET-A and ET-B receptors in equine bronchi. Further studies are needed to 
establish the exact nature of this receptor interaction. Furthermore, we reported the importance of 
epithelium in the regulation of ET-1 induced bronchial tone in horses. We believe that the 
findings of the current study could form a basis for the future clinical studies to develop a 
therapeutic regimen using ET-B receptor antagonists. 
2.6 Footnotes  
a Esophageal balloon, AE Medical, Farmingdale, NJ. 
b Model 7D polygraph, Grass Medical Instrument Division of Astro-Med, Inc.West    Warwick, 
RI. 
 
c Sodium pentobarbital (Beuthanasia solution), Scherring-Plough Animal Health Corp, 
Kenilworth, NJ. 
 
d Grass model FT.03, Grass Medical Instrument Division of Astro-Med, Inc, West Warwick, RI 
 
e  ET-A receptor antagonist, BQ-123 and ET-B receptor antagonist, IRL-1038, American Peptide, 
Inc, Sunnyvale, CA 
 
f Graphpad Prism Verion 4.0, GraphPad Software, Inc., San Diego, CA. 
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CHAPTER 3. EXPRESSION OF ENDOTHELIN RECEPTORS IN THE BRONCHIAL 
SMOOTH MUSCLE AND EPITHELIUM OF CLINICALLY HEALTHY AND SUMMER 
PASTURE-ASSOCIATED OBSTRUCTIVE PULMONARY DISEASE (SPAOPD)-













3.1 Introduction  
Recurrent airway obstruction (RAO) is a common pulmonary condition affecting 
numerous horses worldwide (Bowles et al. 2002). There are basically two forms of RAO. One is 
chronic obstructive pulmonary disease (COPD) which occurs in stabled horses in winter months. 
The other form which is known as summer pasture-associated obstructive pulmonary disease 
(SPAOPD) mainly occurs in grazing horses in summer months in the Southeastern United States 
(Bowles et al. 2002). These are severely debilitating diseases characterized by airway 
inflammation, bronchoalveolar lavage fluid (BALF) neutrophilia, bronchial spasm, mucus 
hypersecretion, chronic cough and dyspnea.  Equine SPAOPD mainly affects mature horses, 
which work at sub-maximal intensities most of the time. Affected horses show reluctance to 
work and exercise intolerance (Art et al. 1998). In inflammatory airway diseases such as 
SPAOPD and asthma, many inflammatory mediators such as histamine, bradykinin, and 
endothelin-1 are released in the lungs during the periods of disease exacerbation (Mattoli et al. 
1991, Robinson et al. 1996, Benamou et al. 1998). Some of these mediators cause potent 
bronchial spasm which decreases airway caliber, resulting in hypoxia, hypoxemia and 
subsequent ventilation/perfusion mismatching (Mattoli et al. 1991, Robinson et al. 1996).  
Endothelin-1 (ET-1) is a multi-functional 21 amino acid peptide, which was first isolated 
from porcine aortic endothelial cells (Yanagisawa et al. 1988). It has an important role in the 
maintenance of vascular and airway tone (Benamou et al. 1998). It elicits its effects, including 
smooth muscle contraction, by acting through two types of receptors, namely endothelin A (ET-
A) and endothelin B (ET-B). It can also cause vasodilatation and bronchodilatation by releasing 
nitric oxide and prostaglandin E2 (PGE2) from vascular endothelium and airway epithelium, 
respectively. Additionally, by acting through ET-B receptors, ET-1 can potentiate cholinergic 
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nerve-mediated contractions of isolated mouse and human tracheae (Henry and Goldie 1995, 
Fernandes et al. 1996). It has also been demonstrated that ET-1 can induce the release of 
acetylcholine from nerve endings by acting through ET-A and ET-B receptors in isolated rat and 
rabbit tracheae (Yoneyama et al. 1995, Knott et al. 1996). ET-1 can also cause 
bronchoconstriction by releasing secondary mediators such as thromboxanes and platelet 
activating factor (PAF) (Filep et al. 1990, Battistini et al. 1990). ET-1 stimulates DNA synthesis 
and cell proliferation in various cells, including smooth muscles (Bagnato and Natali 2004). ET-
1 can act as a co-mitogen by acting synergistically with other growth factors including epidermal 
growth factor (EGF), PAF and platelet-derived growth factor (PDGF) (Bagnato and Natali 
2004). ET-1 can also elicit proinflammtory effects on airways, and in pulmonary allergic 
inflammation it upregulates cytokines such as interleukin (IL)-1, IL-8, tumor necrosis factor-α 
(TNF-α), interferon-γ (IFN-γ) and IL-4 (Finsnes et al. 2001, Millul et al. 1991).  
Most of the vital organs in the body synthesize ET-1; however, lung is the primary organ 
of synthesis and degradation of ET-1 (Henry PJ 1999). Important cells that synthesize ET-1 in 
the lungs include vascular endothelial cells, epithelial cells, Clara cells, goblet cells, 
neuroendocrine cells, smooth muscle cells, platelets, mucus cells, serous cells, parasympathetic 
ganglia within the airways, and alveolar macrophages (Henry PJ 1999, Sirvio et al. 1990, Giaid 
et al.  1991, McKay et al. 1991a). In lungs, the greatest density of ET receptors is present in 
smooth muscles and the alveolar septae (Henry PJ 1999).       
Pulmonary ET-1 levels are shown to be increased in human COPD, experimental allergic 
inflammation in rats, bronchiectasis, bronchiolitis obliterans, bleomycin-induced pulmonary 
fibrosis in rats and in cultured rat pulmonary endothelial cells subjected to oxidant stress (Roland 
et al. 2001, Salmon et al. 2000, Zheng et al. 2000, Schersten et al. 1996, Mutsaers et al. 1998, 
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Michael et al. 1997). Similarly, Benamou et al., reported that the ET-1 levels in the systemic 
circulation and bronchoalveolar lavage fluid (BALF) are greater in horses affected with RAO 
than those of normal horses (Benamou et al. 1998). These researchers also demonstrated the 
spasmogenic action of ET-1 in the isolated third generation pulmonary arteries and bronchi in 
horses. In these studies, they showed that ET-1 elicits bronchial constriction in horses by acting 
through both ET-A and ET-B receptors (Benamou et al. 2001, Benamou et al. 2003). This close 
relationship between ET-1 and lungs has prompted us to conduct preliminary in vitro 
pharmacological studies, which revealed that ET-1 can induce significantly exaggerated 
bronchoconstriction in SPAOPD horses, when compared with healthy horses.a, b, c This result had 
prompted us to hypothesize that ET receptors are altered in the bronchi of SPAOPD-affected 
horses. In this study, we particularly wanted to investigate ET receptor alterations in bronchial 
epithelium and smooth muscles because these are not only the most affected tissues in 
obstructive pulmonary diseases but also are rich sources of ET receptors (Henry PJ 1999, McKay 
et al. 1991). Therefore, any findings regarding alterations in the levels of ET receptors in these 
tissues could help us to better understand the role of ET-1 and its receptors in the pathogenesis of 
SPAOPD. Additionally, it is reported that equine as well as human COPD does not uniformly 
affect the entire lungs (Benamou et al. 2003, Kaup et al. 1990, Saito and Thurlbeck 1995). In the 
current study, the gross pathological changes that we noticed in the post-mortem evaluation of 
the lungs of SPAOPD-affected horses were not uniformly distributed throughout the lungs. 
Therefore, we wanted to investigate if there is any interlobar difference in the receptor alteration 
in SPAOPD-affected horses. Hence, the purpose of the study reported here was to determine and 
compare the expression of ET receptors immunohistochemically in bronchial smooth muscles 
and epithelium among five lung lobes of clinically healthy and SPAOPD-affected horses.    
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3.2 Materials and Methods 
3.2.1 Horses – This study was approved by the Institutional Animal Care and Use Committee of 
Louisiana State University. All horses were procured by donation. All SPAOPD-affected horses 
had a history of signs of obstructive pulmonary disease after they were exposed to pasture in the 
summer. Eight clinically healthy (or control) horses (2 females, 5 geldings, 1 stallion; 6 Quarter 
horses, 1 Paint, 1 Arabian), 10 to 20 years old (mean ± SD, 15.6 ± 3.3 years) and eight 
SPAOPD-affected horses (3 geldings, 1 stallion, 4 females; 3 Quarter horses, 1 Appaloosa, 1 
Thoroughbred, 3 Paint), 10 to 20 years old (mean ± SD, 14.8 ± 2.4 years) were included.  
3.2.2 Clinical Evaluation – On the day of clinical evaluation, we observed the general demeanor 
and respiratory behavior of the horse. Rectal temperature (oF), heart rate (beats/min), respiratory 
rate (breaths/min), nostril flare and abdominal lift were recorded. In addition, we assessed 
respiratory sounds by auscultation. Finally, clinical score (CS) and change in transpleural 
pressures (∆ Ppl) were determined.  
3.2.3 Clinical Scoring (CS) – Clinical scores were determined by use of the following algorithm 
(Seahorn et al. 1997). 
                  CS = (Medial nostril flare + Lateral nostril flare)/2 + Abdominal lift 
Each of the variables in the above algorithm was scored from 0 to 4. A score of “0” indicates that 
the nostril had little movement and the ventral flank showed little or no movement. A score of 
“4” indicates that the nostril remained maximally flared throughout the respiratory cycle and the 
abdominal lift resulted in a “heave line” that extended cranially to the 5th intercostal space.  
Thus the maximum clinical score is “8”. 
3.2.4 Change in Transpleural Pressure ( Ppl) – The change in transpleural pressure ( Ppl) was 
measured indirectly by using an esophageal balloond secured over the end of a cathetere 
 92
connected to a pressure transducerf interfaced with a polygraphg. A 10-cm long, 3.5 cm 
circumference balloon was placed over the end of a 2-m long, 2-mm diameter canula. The 
balloon was inserted through a lubricated nasogastric tube that was passed into the rostral 
esophagus. Once the balloon was located between the heart and diaphragm, the nasogastric tube 
was removed. The balloon was inflated with 1.5 ml of water and measurements were recorded 
for one minute. Changes in the esophageal pressure (peak inspiratory minus peak expiratory 
pressures) during tidal breathing reflect the change in transpleural pressure.  
3.2.5 Grouping – For inclusion in the study, all horses must have had normal reference values of 
rectal temperature (~38.6 oC), heart rate (~30 to 40 per minute), respiratory rate (~10 to 20 per 
minute) and thoracic auscultation. In addition, none of the horses included in this study had 
received any medication at least 7 days prior to clinical evaluation. To be included in the 
SPAOPD-affected group, in addition to the history of SPAOPD, the horses must have had a CS  
5.0 and a change in Ppl > 15.0 cm of H2O.  
3.2.6 Tissue Collection and Processing – The day after grouping, horses were humanely 
euthanatized using an intravenous overdose (90 mg/kg) of sodium pentobarbitalh. Gross post-
mortem evaluation of the lungs was made before removing them from the thoracic cavity. Three 
samples each measuring approximately 3 x 3 cm were prepared from each of the five lobes 
(Right diaphragmatic, Left diaphragmatic, Right apical, Left apical and Accessory) of the lungs. 
It was ensured that each sample that was collected contained at least one bronchus (~ 4 - 8 mm 
wide). The samples were immediately immersed in zinc-formalin and were fixed for 12 hours. 
Fixed samples were dehydrated with graded concentrations of ethyl alcohol (70%, 90% and 
100%) and subsequently cleared with xylene.  Finally, the samples were embedded in paraffin. 
These paraffin blocks containing tissue sections were stored at room temperature until used for 
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immunohistochemistry studies. Rat lung samples, which were used as positive controls, were 
also collected in a similar manner (Wendel et al. 2004). For Western blotting, equine lung 
samples (containing ~ 4 to 8 mm wide bronchi) and rat lung samples (used as positive controls) 
were collected, snap frozen in liquid nitrogen and stored at -80oC. 
3.2.7 Antibodies and Controls – The anti ET-A receptor polyclonal primary antibodiesi that 
were used in the present study were raised in sheep against the immunogen sequence (Q410-E-Q-
N-H-N-T-E-R-S-S-H-K422 amino acid residues), which is part of the C-terminal region of rat ET-
A receptor. Similarly, anti ET-B receptor polyclonal primary antibodiesj were raised in sheep 
against the immunogen sequence (K424-A-N-D-H-G-Y-D-N-F-R-S-S-N-N438 amino acid 
residues), which is a part of the C-terminal region of rat ET-B receptors. The ET-B receptors of 
horse and rat share 85% homology (Yang et al. 1998). Moreover, the C-terminal peptide of rat 
ET-B receptor that was used to generate antibodies bears 100% homology to the C-terminal 
region of equine ET-B receptor at the 424-438 amino acid locations. This observation is based on 
the sequence similarity search on Swiss Institute of Bioinformatics (SIB) Basic Local Alignment 
Search Tool (BLAST) network service. However, ET-A receptors are not yet sequenced in 
horses. Owing to the extreme conservation of ET receptor sequences in mammalian species, we 
assumed that the antibodies raised against rat ET-A receptors would cross react with equine ET-
A receptors (Yang et al. 1998). To confirm the antibody cross-reactivity, we performed Western 
blot analysis. In addition, we included the necessary positive and negative controls in 
immunohistochemistry studies. 
3.2.8 Western Blotting to Validate Primary Antibodies – Lung protein extracts were prepared 
by homogenizing the thawed equine and rat lung samples in Camiolo buffer [0.075M Potassium 
acetate, 0.3M NaCl, 0.1M L-arginine basic salt, 0.01M EDTA-HCl and 0.25% Triton X-100] 
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containing a protease inhibitor cocktailk. Extracts were clarified by centrifugation (10,000g for 
15 min at 4oC). Supernatant fractions were assayed for protein concentration, using Bradford 
reagent l and used for Western blot analysis. Western blot analysis was performed as previously 
described (McMullan et al. 2001, Black et al. 1997). Briefly, protein extracts (150 µg) were 
separated on 10% denaturing polyacrylamide gels for ET-A and ET-B receptors. Pre-stained 
color protein markers were also run in the gel. All gels were electrophoretically transferred to 
polyvinylidene fluoride membranes. The membranes were blocked with 5% nonfat dry milk in 
Tris-buffered saline containing 0.1% Tween. After blocking, the membranes were incubated for 
1 hour at room temperature with 1:500 dilution of either ET-A or ET-B antisera, washed with 
Tris-buffered saline containing 0.1% Tween, and then incubated with donkey anti-sheep IgG-
horseradish peroxidase conjugate.m After washing, protein bands were visualized by enhanced 
chemiluminescencen according to manufacturer’s instruction using Bio-Max MR film. o Protein 
band sizes were determined by using Quantity One Image analysis software.p 
3.2.9 Preparation of Slides for Immunohistochemistry – Among the three paraffin blocks 
from each lobe of the lung, the block with a bronchus closest to the desired diameter (4-8 mm) 
was selected. From the selected paraffin block, tissue sections measuring 4 µm in thicknesses 
were cut with a microtome and mounted on clean sialinized slides. From each paraffin block, 
three slides were prepared. Two of three slides were used for detecting the ET receptors (ET-A 
and ET-B). The other slide was used as a negative control.  These tissue sections were 
deparaffinized with xylene and subsequently rehydrated with graded concentrations of ethyl 
alcohol (100%, 90% and 70%), respectively. Then all of the slides were subjected to 
immunohistochemistry staining (Furuya et al. 2005, De Falco et al. 2002). 
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3.2.10 Immunohistochemistry – The automated Dako Autostainerq was used to perform the 
immunohistochemistry studies. Optimization of the antibody showed that the staining was best 
when no antigen retrieval method was used. Except when noted, all the rinsing steps were 
conducted with TRIS-Buffered Saline (TBS) at pH 7.6 containing 0.05% Tween-20. After 
rinsing the slides with TBS, the endogenous peroxidase activity of the tissues was blocked by 
applying 3% H2O2 for 10 min. Sections were then rinsed and endogenous avidin and biotin were 
blocked for 10 minutes each by using avidin/biotin blocking agentr. After rinsing all of the slides, 
endogenous protein was blocked for 30 minutes at room temperature by adding normal rabbit 
serums. Manufacturer’s guidelines were followed to prepare the blocking serum. After blowing 
off the excess blocking serum, the tissue sections on the slides were incubated with either sheep 
anti ET-A receptor polyclonal primary antibodiesi or sheep anti ET-B polyclonal primary 
antibodiesj at 1:200 dilutions each, for 30 minutes at room temperature. In the negative controls, 
the primary antibody was replaced by sheep gamma globulint at 1:1,000 dilutions. Antibodies 
and sheep gamma globulins were diluted in DAKO antibody diluentq. After rinsing all of the 
slides, biotinylated rabbit anti-sheep IgG secondary antibodiess were applied to the sections for 
30 minutes. After rinsing the slides, Vectastain elite ABC immunoperoxidase systems was 
applied to the tissue sections. Then, all of the tissue sections were washed with TBS. Sites of 
immunostaining were visualized by developing sections in Nova redu (substrate for peroxidase), 
which was applied to the sections for 8 minutes. After washing with TBS followed by deionized 
water, the slides were counterstained with Mayer’s hematoxylin for 5 minutes. Then, the slides 
were thoroughly washed with TBS and deionized water, respectively. The sections were 
dehydrated through graded concentrations of ethyl alcohol and cleared with xylene. Finally, the 
sections were mounted with Permount and glass cover slips and allowed to dry.  
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3.3 Image Analysis 
            Photographs of the stained slides were obtained with a Spot RT Color camerav on a 
Nikon E400 microscopew at 20X magnification. Corresponding software was used to calibrate 
the image set up parameters before capturing the images. Light intensity and exposure settings 
were kept constant for all photographs. A total of five photographs were captured per slide. 
Photographs were exported to Image-Pro Plus 4.1.1.2x software for analysis. Using the software, 
colored markers were applied on the images to differentiate the color of immunostained tissue 
with the other colors (Francisco et al. 2004). The red color marker was applied to the 
immunostained sections of the tissues, whereas blue, light blue and yellow color markers were 
applied to the stained colors of nuclei, non-specific tissue, and white background of the slide, 
respectively (Figure 3.1). These colored markers represent the intensity of staining. For 
example, the greater the intensity of immunostaining, the greater is the pixel value for the red 
color marker and hence the greater is the percentage total per area for red color marker. 
           A template image was created by using a positive control slide in which the 
aforementioned colored markers were applied. This template was used to attribute the color 
markers to all of the slides under analysis. Total area of the tissue of interest (either bronchial 
epithelium or bronchial smooth muscle) was manually selected. It was ensured that the white 
background did not exceed more than 10% of the total area selected. Percentage of 
immunostained area (total stained area/total selected area multiplied by 100) of the tissue was 
determined for each of the five photographs taken. This procedure was applied to all three types 
of slides, i.e., the slide to which the ET-A antibody was applied, the slide to which the ET-B 
antibody was applied and the slide which was used as a negative control. Percentage of 
immunostained area on the negative control slide was subtracted from the percentage of total 
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immunostained area of either of the other slides. The data for five images were averaged and 
exported to MICROSOFT EXCELy. 
 
Figure 3.1. Colored markers were applied by using image analysis software to determine the 
percentage of immunostained area in a selected tissue of interest. The arrows in the figure 
indicate the immunostaining color.            
 
3.4 Statistical Analyses  
           The CS and Ppl data were reported as median and range values. These variables were 
compared between clinically healthy and SPAOPD-affected horses, using the Mann-Whitney 
test. The immunohistochemical data was analyzed by using two-way ANOVA and pair-wise 
         500 µm 
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comparisons were made by employing post-hoc Bonferroni tests. For epithelium and smooth 
muscle, the following three comparisons were made. First, in all five lung lobes, comparisons 
were made between clinically healthy and SPAOPD-affected horses to determine the differences 
in receptor expression between the two groups. Second, comparisons were made in both groups 
within the five lobes to determine the interlobar differences in receptor expression. Third, in both 
groups of horses, comparisons were made to determine the differences of expression between 
ET-A and ET-B receptor sub-types in all of the lung lobes. In addition, in both groups of horses, 
comparisons were made to determine the differences in the receptor expression between 
epithelium and smooth muscle of all the lung lobes. Finally, data from all of the lung lobes was 
pooled and all the comparisons just mentioned were made to determine the receptor expression 
differences in the whole lung. A P ≤ 0.05 was considered statistically significant for all the tests. 
All the tests were analyzed using the SAS 9.1.2z version of the software. 
Table 3.1– Signalment, clinical variables, clinical score, and ∆Ppl for SPAOPD-affected horses 
and healthy horses. * Clinical score assigned on a scale of 0 to 8. a,b Values with different 
superscript letters differ significantly (P ≤ 0.05). y = years, bpm = beats per minute, rpm = 
respirations per minute, CS = clinical score and ∆Ppl = transpleural pressure 
 
        SPAOPD-affected horses Healthy horses 
Variable Median Range Median Range 
Age (y) 14.8 10-20 15.6 10-20 
Temp (oC) 37.8 37-38.9 38.0 37.8-38.9 
HR (bpm) 46 35-66 39 36-60 
RR (rpm) 26 18-40 21 18-24 
CS* 5.5 5.0-6.0 1.5 1.0-3.5 
∆Ppl (cm H2O)* 25a 20-32 7b 4.0-9.0 
 
 3.5 Results 
3.5.1 Clinical Evaluation and Grouping – In all horses, the mean values of heart rate, 
respiratory rate and rectal temperature were close to the reported normal values (Table 3.1).  
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 All horses were in good body condition and had a normal appetite and demeanor. All SPAOPD-
affected horses had respiratory wheezes on auscultation, nostril flaring, increased abdominal lift 
and cough. Few SPAOPD-affected horses showed a marked ‘heave’ line extending along the 
abdominal wall. The SPAOPD-affected horses had a CS (median 5.50; range, 5.0 to 7.0) 
significantly greater than clinically healthy horses (median 1.5; range, 1.0 to 3.5).  Similarly, the 
Ppl of SPAOPD-affected horses (median 25.0 cm of H2O; range 20 to 32) were significantly 
greater than clinically healthy horses (median 7.0 cm of H2O; range, 4.0 to 9.0; Table 3.1).       
3.5.2 Post Mortem Assessment of Lungs – All SPAOPD-affected horses had hyperinflated 
orange-pink colored lungs. The lungs did not collapse after the thoracic cavity was opened. Some 
regions of the lungs had a tough texture and a marked difficulty was noted during excision of 
samples from those regions. Lungs of many affected horses showed distinct pale fibrotic patches 
distributed non-uniformly on the surface. The surface of the lungs of some affected horses had 
indentions or impressions caused by the pressure from the ribs. Mucus plugs were observed in 
the airways; however, this observation was also not uniform throughout the lung fields. Lungs of 
healthy horses were of normal size, normal texture and were pale pink in color. None of them 
had noticeable fibrotic patches or rib impressions on the surface. Samples were easy to excise 
and the lungs collapsed immediately and completely after opening the thoracic cavity. On only a 
few occasions were mucus plugs noticed inside the bronchi.  
3.5.3 Antibody Specificity – Western blotting analysis revealed that the band sizes of either ET-
A or ET-B receptors were identical in rat and horse lung samples (Fig 3.2).  In 
immunohistochemistry, rat lung sections showed intense immunostaining for both receptors and 
no staining was observed in negative controls (Figures 3.3, 3.4 and 3.5).  Similarly, the horse 
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lung sections showed immunostaining for both receptors and no staining was detected in the 
negative controls (Figures 3.6 and 3.7). 
                 
 
Figure 3.2 − Western blotting of ET receptors was used to confirm the specificty of the primary 
antibodies used in the immunohistochemistry studies. Rat lung tissues were used as positive 
controls. Lane 1 and 3 demonstrate the bands for rat ET-A and ET-B receptors, respectively. 
Lane 2 and 4 illustrate the bands for equine ET-A and ET-B receptors. For all of the bands, the 
molecular weight was ~ 55 Kd.  
     
      ~55 Kd 
    ET-A                   ET-B 




Figure 3.3 − Photomicrograph of the immunostaining of rat bronchial tissue which was used as 
negative control (20X magnification). In this control, the primary antibody was replaced with 
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Figure 3.4 − Photomicrograph of the immunostaining of rat bronchial tissue using anti ET-A 
receptor primary antibody, which was used as a positive control (20X magnification). The same 
tissue was used as that of the negative control. The arrows in the figure indicate the color of ET-














Figure 3.5 − Photomicrograph of the immunostaining of rat bronchial tissue using anti ET-B 
receptor primary antibody, which was used as positive control (20X maginification). The same 
tissue was used as that of the negative control. The arrows in the figure indicate the color of ET-
B receptor immunostaining. 
C 
            500 µm 
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Figure 3.6. Photomicrograph of the immunostaining of equine bronchial tissue, which was used 
as a negative control (20X maginification). Tissue from an SPAOPD-affected horse is shown. 
The primary antibody is replaced with sheep gamma globulin. 
 
 
          500 µm
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Figure 3.7. Photomicrograph of the immunostaining of equine bronchial tissue to which anti ET-
B antibody is applied (20X magnification). The same tissue as that of the negative control is 
shown here. Staining of bronchial smooth muscle and bronchial epithelium can be clearly 
observed. The arrows indicate the color of ET-B receptor immunostaining. 
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Figure 3.8 − Mean ± SEM percentages of immunostained area for ET-A receptor in bronchial 
epithelium of healthy horses (white bars), bronchial smooth muscle of healthy horses 
(horizontal-striped bars), bronchial epithelium of SPAOPD-affected horses (crosshatched bars), 
and bronchial smooth muscle of SPAOPD-affected horses (black bars). * Within SPAOPD-
affected horses, value differs significantly (P < 0.05) from the value for bronchial epithelium. 
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Figure 3.9 – Mean ± SEM for percentage of ET-B receptor immunostained area of bronchial 
epithelium and smooth muscle of healthy and SPAOPD-affected horses. The * indicates a 
statistically significant (P < 0.05) difference in the percentage of immunostained areas between 
epithelium and smooth muscle of SPAOPD-affected horses. The † indicates a statistically 
significant (P < 0.05) difference in the percentage of immunostained areas between smooth 
muscle of healthy and SPAOPD-affected horses. 
 

























Figure 3.10 – Mean ± SEM for percentage of ET-A receptor immunostained area in different 
lung lobe sections: RD= right diaphragmatic, LD= left diaphragmatic, RA= right apical, LA= left 
apical and AC= accessory. The * indicates a statistically significant (P < 0.01) difference in the 
percentage of immunostained areas (in LD, RA and LA) between epithelium and smooth muscle 
of SPAOPD-affected horses. The † indicates a statistically significant (P < 0.05) difference in 
the percentage of immunostained areas (in LD) between smooth muscle of healthy and 
SPAOPD-affected horses. 
 
3.5.4 Immunostaining – Changes in the Whole Lungs: Pooled data analysis revealed that in 
SPAOPD- affected horses, the percentage of immunostained area of bronchial smooth muscle 
ET-A receptors was significantly greater than that of epithelium; however, this percentage was 
not significantly greater than the smooth muscle ET-A receptors of healthy horses (Figure 3.8).    
In addition, there was no statistical difference in the percentage of immunostaining of ET-A 
receptors between epithelium and smooth muscles of healthy horses. Similarly, there was no 
statistically significant difference in the percentage of immunostaining of epithelial ET-A 
receptors between healthy and SPAOPD-affected horses. Regarding ET-B receptors, pooled data 
analysis revealed that in SPAOPD-affected horses bronchial smooth muscles showed 
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significantly greater percentage of immunstaining than that of epithelium (Figure 3.9).  
However, there was no difference in the immunostaining between epithelium and smooth 
muscles of healthy horses. Bronchial smooth muscle ET-B receptors of SPAOPD-affected horses 
showed a significantly greater percentage of immunostaining than that of healthy horses.  
However, there was no difference in the immunostaining of epithelial ET-B receptors between 
healthy and SPAOPD-affected horses. 
         On the whole, there was no difference in the percentage of immunostaining between ET-A 
and ET-B receptors of either epithelium or smooth muscles of normal and SPAOPD-affected 
horses.  
Interlobar Differences: Specimens from the five lung lobes of SPAOPD-affected horses 
showed a greater percentage of ET-A receptor immunostained area in the bronchial smooth 
muscle when compared to that of normal horses (Figure 3.10). 
In SPAOPD-affected horses, the percentage of immunostained area was ~45% in the bronchial 
smooth muscle of four out of five lobes, whereas the percentage was < 30% in the smooth 
muscles of all five lobes in the control horses. However, the difference was statistically 
significant only in the case of the left diaphragmatic lobe. Additionally, in both groups of horses, 
no difference in the percentage of smooth muscle ET-A receptor immunostaining was observed 
among the lobes. Similarly, no difference was observed in the percentage of immunostained area 
of bronchial epithelial ET-A receptors between control and SPAOPD-affected horses or among 
the five lobes of both groups of animals. In control horses, no difference was observed in the 
percentage of immunostained area of ET-A receptors between epithelium and smooth muscles. 
However, in SPAOPD-affected horses, all lung lobes showed a tendency for greater percentage 
of immunostained area of bronchial ET-A receptors in smooth muscle compared with the 
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epithelium. This difference was statistically significant in all lung lobes except the right 
diaphragmatic and accessory lobes. 
Regarding ET-B receptors, specimens from the five lung lobes showed a greater 
percentage of immunostained area in the bronchial smooth muscles of SPAOPD-affected horses 



























Figure 3.11 – Mean ± SEM for percentage of ET-A receptor immunostained area in different 
lung lobe sections: RD= right diaphragmatic, LD= left diaphragmatic, RA= right apical, LA= left 
apical and AC= accessory. The * indicates a statistically significant (P < 0.01) difference in the 
percentage of immunostained areas (in RD, LD, RA and LA) between epithelium and smooth 
muscle of SPAOPD-affected horses. The † indicates a statistically significant (P < 0.05) 
difference in the percentage of immunostained areas (in LD, RA, LA and AC) between smooth 
muscle of healthy and SPAOPD-affected horses. 
 
In SPAOPD-affected horses, bronchial smooth muscles of all the lobes showed a 
percentage of immunostained area in the range of 35 to 50%, whereas, the percentage of 
immunostained area was < 25% in all of the lobes in control horses. The difference was 
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statistically significant in all of the lobes except in the right diaphragmatic lobe (P = 0.08). No 
lung lobe showed a tendency of greater expression of smooth muscle ET-B receptors than the 
others in either group of animals. No difference was observed in the percentage of 
immunostained area of bronchial epithelial ET-B receptors between control and SPAOPD-
affected horses and among the five lung lobes of both groups of animals. In control horses, no 
difference was observed in the percentage of immunostained areas of ET-B receptors between 
epithelium and smooth muscle. As in the case of ET-A receptors in SPAOPD-affected horses, all 
of the lobes showed a tendency for a greater percentage of immunostained area of bronchial ET-
B receptors in smooth muscle compared with epithelium. This difference was statistically 
significant in all lobes except the accessory lobe. 
Finally, there was no difference in the percentage of immunostaining between ET-A and 
ET-B receptors of either epithelium or smooth muscle in all of the lung lobes of normal and 
SPAOPD-affected horses. 
3.6 Discussion 
            This study revealed several important findings regarding the potential role played by ET-
1 and its receptors in the pathogenesis of equine SPAOPD. First, both ET-A and ET-B receptors 
are present in bronchial epithelium as well as bronchial smooth muscle of both healthy and 
SPAOPD-affected horses. Second, both ET-A and ET-B receptors are equally distributed in 
bronchial epithelium of either control or SPAOPD-affected horses. Similarly, both of these 
receptors are equally distributed in the bronchial smooth muscle of either control or SPAOPD-
affected horses. Third, in the bronchial epithelium, distribution of the ET-A or ET-B receptors in 
SPAOPD-affected horses is not different from control horses. In other words, there is no 
alteration in receptor density in the epithelium of diseased horses. Finally, in the bronchial 
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smooth muscle, there is an up-regulation of ET-A receptors in the left diaphragmatic lung lobe 
and of ET-B receptors in all of the lung lobes except the right diaphragmatic in SPAOPD-
affected horses when compared to control horses.  
An important feature of airway hyperreactive diseases is obstruction of airways, 
particularly at the level of the bronchi (Parker 2004). The hyper-inflation of the lungs that we 
noticed during post-mortem analysis of SPAOPD-affected horses was because of air entrapping 
in post-obstructive areas of the lung. Hence, it is not a true emphysematous condition as is often 
observed in human COPD. This hyper-inflation was the cause of the rib impressions that were 
observed on the surface of the lungs. Because of the entrapped air, SPAOPD-affected lungs did 
not collapse when the thoracic cavity was opened. Airway obstruction can be caused mainly by 
three factors: constriction of airway smooth muscle, thickening of airway walls due to smooth 
muscle hyperplasia and/or hypertrophy, and accumulation of mucus or other secretions in the 
airway lumen. Among these three causes, constriction of airway smooth muscle, especially those 
of the bronchi (i.e. bronchoconstriction), is the most important (O'Byrne PM and Inman MD 
2003). Bronchoconstriction in obstructive pulmonary diseases can be caused by several 
inflammatory mediators released into the airways. Some of these mediators include histamine, 
PAF, prostaglandins, bradykinin and ET-1 (Robinson et al. 1996). ET-1 induced 
bronchoconstriction is well established in human obstructive pulmonary diseases (Mattoli et al. 
1991). Additionally, Benamou et al. demonstrated that ET-1 is a potent constrictor of bronchial 
as well as vascular smooth muscles of equine lungs.  Besides being one of the important agents 
causing bronchoconstriction, ET-1 is also an important factor causing airway remodeling and 
mucus hypersecretion in obstructive pulmonary diseases (Goldie and Fernandes 2000). 
Bronchoconstriction elicited by ET-1 is extremely potent in most mammalian species, both  
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in vivo and in vitro. ET-1 can induce bronchoconstriction by three mechanisms: first by acting 
directly on the smooth muscle ET-A and/or ET-B receptors, second by augmenting the 
cholinergic mediated smooth muscle constriction, and finally by releasing secondary mediators 
such as thromboxanes (Filep et al. 1990). This ET-1 induced bronchoconstriction is significantly 
exaggerated in most of the obstructive pulmonary diseases such as COPD, when compared with 
healthy subjects (Goldie and Fernandes 2000). Even though increased ET-1 levels could serve as 
the main explanation for this exaggerated ET-1 induced bronchoconstriction, another possible 
reason could be the up-regulation of ET-A and/or ET-B receptors in the bronchial smooth 
muscles. Benamou et al. have already established that pulmonary and BAL fluid ET-1 levels are 
elevated in RAO-affected horses (Benamou et al. 1998). In the present study, we demonstrated 
that in four out of five lung lobes there was greater expression of ET-B receptors in the bronchial 
smooth muscle of SPAOPD-affected horses when compared with normal horses. As far as ET-A 
receptors are concerned, all of the lung lobes showed a tendency of greater expression in the 
smooth muscle of SPAOPD-affected horses. However, the difference was statistically significant 
only in the case of left diaphragmatic lobe. We believe that the non-significance of the over 
expression of ET-A receptors in all the other lobes of SPAOPD affected horses was because of 
the small sample size (n=8 in each group of horses) in this study and also the inherent variability 
in the intensities of this naturally acquiring disease.  
Airway remodeling constitutes an important pathological change in many airway 
hyperreactive diseases including equine COPD (Kaup et al. 1990). It is demonstrated that ET-1 
can cause potent airway smooth muscle hyperplasia in the isolated rabbit and human airway 
smooth muscle cells (Glassberg et al. 1994, Novereal et al. 1992). ET-1 has also been implicated 
in allergen induced airway smooth muscle proliferation in the rat (Martin and Ramos-Barbon 
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2003). Moreover, by acting through ET-A and ET-B receptors, ET-1 can augment the potent 
mitogenic properties of classical growth promoters such as thromboxanes, EGF and PDGF 
(Salmon et al. 2000, Carratu et al. 1997). Our findings of ET receptor alteration in diseased 
horses could form a basis for future studies investigating the role of ET-1 in causing smooth 
muscle hyperplasia, which has been reported in equine COPD (Robinson et al. 1996). 
In healthy subjects, bronchial tone is constantly maintained by a balance between smooth 
muscle constrictor and relaxant agents (Matera et al. 2002). Certain agents such as ET-1 possess 
both smooth muscle contraction and relaxation properties. ET-1 elicits smooth muscle relaxing 
effects by acting through both ET-A and ET-B receptors present on the epithelial lining of the 
airways. By acting through these receptors, ET-1 causes the release of bronchodilator agents like 
nitric oxide and PGE2 (Emanueli et al. 1998, Hay et al. 1993b). In obstructive pulmonary 
diseases such as SPAOPD, the balance between bronchodilation and bronchoconstriction is 
disturbed either due to alterations in the concentrations of airway tone modulators or alterations 
in their receptors. For example, the levels of bronchomodulators such as histamine, adenosine 
and their receptors are altered in the lungs of patients affected with asthma (O’Byrne and Inman 
2003). Similarly, pulmonary and peripheral ET-1 levels are shown to be up-regulated in equine 
COPD (Benamou et al. 1999). In the present study, we showed that in healthy horses, there is no 
difference in either the ET-A or ET-B receptor population between epithelium and smooth 
muscles. In other words, the quantity and distribution of ET-A and ET-B receptors were similar 
between epithelium and smooth muscle. However, in SPAOPD-affected horses, the relative 
levels of these receptors are shifted toward smooth muscles. In other words, smooth muscles 
tended to show greater expression of receptors compared with the epithelium. This could be an 
important cause in the disturbance of the physiological equilibrium between bronchodilating and 
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bronchoconstricting actions of ET-1 leading to an enhanced bronchoconstriction in diseased 
horses.  
The relative proportion of ET receptors in the airway smooth muscle is species-specific.  
Human bronchial smooth muscle from non-diseased lungs contains a greater proportion of ET-B 
receptors compared with ET-A, whereas tracheal smooth muscle from rats and mice contain 
approximately equal proportions of the two receptors subtypes (Henry 1999). In the bronchial 
smooth muscle of pigs, the ratio of ET-A to ET-B receptors is 70:30 (Henry 1999). Such species-
specific differences in the relative proportions of these two receptor populations within airway 
smooth muscles could be correlated to the species specific differences in the intensity of 
complications caused by ET-1 in obstructive pulmonary diseases. Such differences in relative 
proportions of ET receptors can also be correlated with the type of predominant physiological 
role exerted by ET-1 in healthy subjects. In the present study, we observed that in both groups of 
horses, the relative proportion of ET-A and ET-B receptors is equivalent in smooth muscle and 
epithelium. 
In conclusion, for the first time we have demonstrated that ET-B receptor expression is 
enhanced in the bronchial smooth muscle of SPAOPD-affected horses when compared to those 
of control horses. In this study, we also showed that ET-A receptors tend to be over-expressed in 
the bronchial smooth muscle of SPAOPD-affected horses. Both of these receptors, known to 
have potential roles in the pathogenesis of many obstructive pulmonary diseases such as asthma, 
were shown that they also could play an important role in the pathogenesis of SPAOPD. Further 
studies are warranted regarding the exact role of each receptor in the pathogenesis of this disease. 
Clinical trials using ET receptor antagonists could reveal certain findings which might have 
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clinical relevance in developing a therapeutic strategy to treat this progressive career-ending 
disease. 
3.7 Footnotes 
a  Polikepahad S, Moore RM, Krishnakumar S et al. Pharmacological characterization of 
endothelin receptor responses of bronchi in clinically healthy horses and those affected with 
summer pasture associated obstructive pulmonary disease. Abstract # 653.7; FASEB Journal 
2003; 17 (4); A1047. 
 
b  Polikepahad S, Moore RM, Venugopal C et al. Effects of epithelial denudation on endothelin-1 
induced bronchoconstriction in clinically healthy and summer pasture associated obstructive 
pulmonary disease (SPAOPD) affected horses. Abstract # 172.1; FASEB Journal 2004 18 (4); 
A234. 
 
c Venugopal C, Polikepahad S, Holmes E et al. Evidence for involvement of endothelin-B 
receptors in equine summer pasture associated obstructive pulmonary disease (SPAOPD). 
Abstract # 172.3: FASEB Journal 2004, Washington DC. 
 
d Esophageal balloon, AE Medical, Farmingdale, NJ. 
e Catheter, PE 350 tubing, VWR Scientific Products, Willard, OH. 
f Statham Model P50 pressure transducer, Statham instruments, Hato Ray, Puerto Rico. 
g Model 7D polygraph, Grass Medical Instrument Division of AstroMed, Inc.West Warwick, RI. 
h Sodium pentobarbital (Beuthanasia solution), Scherring-Plough Animal Health Corp, 
Kenilworth, NJ. 
 
i Sheep Antibody to Endothelin A Receptor, BIODESIGN International, Saco, Maine. 
 
j Sheep Antibody to Endothelin B Receptor, BIODESIGN International, Saco, Maine. 
k  Protease Inhibitor Cocktail Tablets, Roche Diagnostics Corporation, Roche Applied Science, 
Indianapolis, IN. 
 
l  Quick Start Bradford Protein Assay Kit 1, Bio-Rad Laboratories, Hercules, CA 
m  Donkey anti-sheep IgG-HRP, Santa-Cruz Biotechnology, Santa Cruz, CA. 
n  Western lightening chemiluminscence reagent, PerkinElmer Life Sciences, Boston, MA. 
o  BioMax MR film, Eastman Kodak Company, Rochester, NY. 
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p Quantity one 1-D image analysis software, Bio-Rad Laboratories,  Hercules, CA. 
q  Dako Autostainer Universal Staining system, DakoCytomation California Inc, Carpinteria, CA. 
r  Avidin/Biotin Blocking Kit, Vector laboratories, Inc., Burlingame, CA. 
s  Vectastain Elite ABC Kit (Sheep IgG), Vector laboratories, Inc., Burlingame, CA. 
t Jackson ImmunoResearch laboratories, Inc., West Grove, PA. 
u Vector NovaRED Substrate Kit for Peroxidase, Vector laboratories, Inc., Burlingame, CA. 
v SPOT RT Color, Diagnostic instruments, Inc.,Sterling heights, MI. 
w Nikon instruments Inc., Melville, NY. 
x Media Cybernetics, Inc., Silver Spring, MD. 
y Microsoft Corporation, Redmond, WA. 
z SAS Institute Inc. Cary, NC. 
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CHAPTER 4. CHARACTERIZATION OF ENDOTHELIN RECEPTORS IN THE 
PERIPHERAL LUNGS OF CLINICALLY HEALTHY AND SUMMER PASTURE-














4.1 Introduction  
Recurrent airway obstruction (RAO) is a common pulmonary condition observed in 
horses worldwide, and is essentially a delayed type of hypersensitivity reaction characterized by 
neutrophilic infiltration into the airway lumen. Characteristic symptoms of this disease include 
chronic cough, exercise intolerance, labored expiratory effort and nasal discharges (Robinson et 
al. 1996). The inflammatory response in this disease is characterized by airway inflammation, 
bronchoalveolar lavage fluid (BALF) neutrophilia, and increased levels of inflammatory 
mediators such as histamine, bradykinin, leukotrienes, platelet activating factor (PAF), 
endothelin-1 and 15-HETE (Robinson et al. 1996). This disease has two forms. The most widely 
reported form is chronic obstructive pulmonary disease (COPD) which is common in more 
temperate regions of the world. The other form, which is known as summer pasture-associated 
obstructive pulmonary disease (SPAOPD), is a seasonal disease afflicting adult horses in the late 
summer and early fall. This form is common in the Southeastern United States where a warm 
and humid climate enhances the growth of certain types of molds in the pasture, which are 
believed to act as potential aeroallergens in susceptible horses (Seahorn et al. 1994). 
Endothelin-1 (ET-1) is a potent smooth muscle constrictor and an inflammatory mediator. 
It elicits its actions by acting through two receptors, namely endothelin-A (ET-A) and 
endothelin-B (ET-B), both of which are G-protein-coupled heptameric transmembrane receptors. 
Physiologically, ET-1 plays an important role in the maintenance of vascular and airway tone 
(Rubanyi and Polokoff 1994). By directly acting through its receptors, ET-1 can cause potent 
contraction of vascular and non-vascular smooth muscles in vivo and in vitro (Rubanyi and 
Polokoff 1994). It can also cause vasodilatation and bronchodilatation by releasing nitric oxide 
and prostaglandin E2 (PGE2) from vascular endothelium and airway epithelium, respectively (de 
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Nucci et al. 1988b, Tsukahara et al. 1994, Martin et al. 2000 and Emanueli et al. 1998). 
Additionally, ET-1 can potentiate cholinergic nerve-mediated contractions of isolated mouse and 
human tracheae by acting through ET-B receptors (Henry and Goldie 1995, Fernandes et al. 
1996). The ET-1 can also induce the release of acetylcholine from nerve endings by acting 
through both ET-A and ET-B receptors in isolated rat and rabbit tracheae (Yoneyama et al. 1995 
and Knott et al. 1996). The ET-1 stimulates DNA synthesis and cell proliferation in various cells 
by synergistically acting as a co-mitogen with other growth factors including epidermal growth 
factor (EGF), platelet activating factor (PAF) and platelet-derived growth factor (PDGF) 
(Bagnato and Natali 2004). The ET-1 can elicit proinflammtory effects on airways. It is 
demonstrated that in experimental pulmonary allergic inflammation, ET-1 can up- regulate 
cytokines such as interleukin (IL)-1, IL-8, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) 
and IL-4 (Finsnes et al. 2001).  
It has been demonstrated that ET-1 plays an important role in the pathogenesis of allergic 
airway diseases of humans and other species. For example, pulmonary ET-1 levels have been 
shown to be increased in human asthma, human COPD and experimental allergic inflammation 
in rats (Finsnes et al. 2001, Roland et al. 2001 and, Hay and Goldie 1998). Similarly, Benamou 
et al. reported that the ET-1 levels in the systemic circulation and BALF are greater in horses 
affected with RAO than those of normal horses (Benamou et al. 1998). These researchers also 
demonstrated the spasmogenic action of ET-1 in the isolated third generation pulmonary arteries 
and bronchi in horses. In these studies, they showed that ET-1 elicits in vitro bronchial 
constriction in horses by acting through both ET-A and ET-B receptors (Benamou et al. 2003). 
In addition, our preliminary pharmacological studies have revealed that when equimolar 
concentrations of ET-1 are applied to the bronchial tissues of healthy and SPAOPD-horses, the 
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ET-1 induced concentration-dependent contraction was significantly greater in SPAOPD-horses 
than that of healthy horses, suggesting that receptor alterations occur in airway hyperreactivity.a  
In the current study, we hypothesized that the expression of ET receptors would be 
altered in the lungs of SPAOPD-affected horses. The objective of the current study was to 
determine and compare the expression of ET receptors in the lungs of clinically healthy and 
SPAOPD-affected horses by employing reverse transcriptase-polymerase chain reaction (RT-
PCR), real time PCR, Western blotting and immunohistochemical techniques. 
4.2 Materials and Methods 
4.2.1 Horses – This study was approved by the Institutional Animal Care and Use Committee of 
Louisiana State University. All horses were procured by donation. All SPAOPD-affected horses 
had a history of signs of obstructive pulmonary disease after they were exposed to pasture in the 
summer (Seahorn and Beadle 1993). Seven clinically healthy (or control) horses, 10 to 20 years 
old (mean ± SD, 15.8 ± 4.1 years) and seven SPAOPD-affected horses, 10 to 20 years old (mean 
± SD, 16.5 ± 3.2 years) were included.  
4.2.2 Clinical Evaluation – On the day of clinical evaluation, we observed the general demeanor 
and respiratory behavior of the horse. Rectal temperature (38.6oC) heart rate (~30 to 40 
beats/min), respiratory rate (~10 to 20 breaths/min), nostril flare and abdominal lift were 
recorded. In addition, we assessed respiratory sounds by auscultation. Finally, the clinical score 
(CS) and transpleural pressures (∆ Ppl) were determined.  
4.2.3 Clinical Scoring (CS) – Clinical scores were determined by use of the following algorithm 
(Seahorn et al. 1997). 
                  CS = (Medial nostril flare + Lateral nostril flare)/2 + Abdominal lift 
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Each of the variables in the above algorithm was scored from 0 to 4. A score of “0” indicates that 
the nostril had little movement and the ventral flank showed little or no movement. A score of 
“4” indicates that the nostril remained maximally flared throughout the respiratory cycle and the 
abdominal lift resulted in a “heave line” that extended cranially to the 5th intercostal space.  
Thus the maximum clinical score is “8”. 
4.2.4 Transpleural Pressure (∆Ppl) – The transpleural pressure (∆Ppl) was measured indirectly 
by using an esophageal balloonb secured over the end of a catheter connected to a pressure 
transducer interfaced with a polygraphc. A 10-cm long, 3.5 cm circumference balloon was placed 
over the end of a 2-m long, 2-mm diameter canula. The balloon was inserted through a lubricated 
nasogastric tube that was passed into the rostral esophagus. Once the balloon was located 
between the heart and diaphragm, the nasogastric tube was removed. The balloon was inflated 
with 1.5 ml of water and measurements were recorded for one minute. Changes in the 
esophageal pressure (peak inspiratory minus peak expiratory pressures) during tidal breathing 
reflect the transpleural pressure.  
4.2.5 Grouping – For inclusion in the study, all horses must have had normal reference values of 
rectal temperature (38.6oC), heart rate (~ 30 to 40 beats/min), respiratory rate (~ 10 to 20 
breaths/min) and thoracic auscultation. In addition, none of the horses included in this study had 
received any medication for at least 7 days prior to clinical evaluation. To be included in the 
SPAOPD-affected group, in addition to the history of SPAOPD, the horses must have had a CS 
> 5.0 and a ∆Ppl > 15.0 cm of H2O. To be included in the healthy group, the horses must have 
had a CS < 4.0 and a ∆Ppl < 10 cm of H2O. 
4.2.6 Tissue Collection and Processing – The day after grouping, horses were humanely 
euthanatized using an intravenous overdose (90 mg/kg) of sodium pentobarbitald. Gross post-
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mortem evaluation of the lungs was conducted while removing them from the thoracic cavity. 
Samples were randomly collected from the same region of each lung lobe in each horse. For the 
immunohistochemistry, five samples, one from each lung lobe, measuring approximately 3 x 3 
cm were collected, placed in zinc-formalin and fixed for 12 hours. Fixed samples were 
dehydrated with graded concentrations of ethyl alcohol (70%, 90% and 100%) and subsequently 
cleared with xylene.  Finally, the samples were embedded in paraffin. These paraffin blocks 
containing tissue sections were stored at room temperature until used for immunohistochemistry 
studies. For the Western blotting, real time PCR and RT-PCR studies, five samples, collected 
from the same region of each lung lobe as the samples for immunohistochemistry, were collected 
from each horse, snap frozen in liquid nitrogen and stored at -80oC. Rat lung samples, which 
were used as positive controls, were also collected in a similar manner for all three studies. 
4.2.7 Antibodies, Primers and Controls – The anti ET-A receptor polyclonal primary 
antibodiese that were used in the present study were raised in sheep against the immunogen 
sequence (Q410-E-Q-N-H-N-T-E-R-S-S-H-K422 amino acid residues), which is part of the C-
terminal region of rat ET-A receptor. Similarly, anti ET-B receptor polyclonal primary 
antibodiese were raised in sheep against the immunogen sequence (K424-A-N-D-H-G-Y-D-N-F-
R-S-S-N-N438 amino acid residues), which is a part of C-terminal region of rat ET-B receptor. 
For PCR, the following primers were used: ET-A (sense – 5` 
CTTGGAGACCTTATCTACGTGGTC  3`and antisense – 
3`TCACACCTGTCCATGTCTCGTCA 5`), ET-B (sense – 5` 
AGTCGAGATGTGTAAGCTGGTGC 3` and antisense – 3` 
TCAATAGACGCTTAGACGGACGACGAAGT 5`) and β -actin (sense – 5` 
AAGGACCTGTACGCCAACAC 3` and antisense – 3` TAAGACCGGAGTAACAGGTG 5`).  
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The ET-B receptors of horse and rat share 85% homology (Yang et al. 1998). Moreover, the C-
terminal peptide of rat ET-B receptor that was used to generate antibodies bears 100% homology 
to the C-terminal region of equine ET-B receptor at the 424-438 amino acid locations. Similarly, 
the ET-B receptor primer that we used in this study has 95% homology with the sequence of ET-
B receptor of rats and humans at the corresponding location on the gene (Yang et al. 1998). 
These observations are based on the sequence similarity search on Swiss Institute of 
Bioinformatics (SIB) Basic Local Alignment Search Tool (BLAST) network service. However, 
ET-A receptors are not yet sequenced in horses. Owing to the extreme conservation of ET 
receptor sequences in mammalian species, we assumed that the antibodies and primers designed 
for rat ET-A receptors would cross react with equine ET-A receptors (Yang et al. 1998). To 
confirm the cross-reactivity of antibodies and primers, we performed preliminary Western blot 
and PCR analyses on rat and equine lung samples. In the immunohistochemistry studies, we also 
used rat lung samples as positive controls. In addition, negative controls were used in all three 
studies. 
4.2.8 RNA Extraction – Five independent replications per horse (n=14) were used for the RT-
PCR studies. By applying RNase Zapf, it was made sure that all the microtubes, gloves and 
equipment were RNAse free. Lung samples were thawed on ice and homogenized in 0.5 mL of 
TRI reagentg with Ultra Turrax T8h.  After homogenization, all samples were allowed to settle for 
5 minutes. To each homogenized sample, 200 µL of chloroform was added immediately and the 
microtubes were vigorously vortexed for 15 seconds. The samples were allowed to settle for 15 
minutes until two phases of liquid were noticed. Then all microtubes were centrifuged at 
16,000X g at 4o C for 15 minutes. The supernatants (~200 to 300 µL) were collected in separate 
microtubes. Approximately 200 to 300 µL of 2-proponol were added to each microtube, mixed 
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and allowed to settle for 10 minutes at room temperature. All microtubes were then centrifuged 
at 16,000X g at 4o C for 10 minutes. Proponol was decanted thoroughly from all the microtubes. 
Subsequently, 300 to 500 µL of 70% ethanol was added to each tube and the microtubes were 
centrifuged at 16,000 X g at 4o C for 6 minutes. Ethanol was thoroughly decanted and the total 
RNA was dissolved in nuclease free DEPC-treated water. Total RNA was quantified by using 
Nano drop ND-1000 spectrophotometeri. 
4.2.9 Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) – The RT-PCR was 
performed as described previously (McMullan et al. 2001).  For reverse transcription, 1.5 µg of 
total RNA was used. To each sample, oligo dT (0.002µM) and dNTPs (0.5µM) were added. The 
mixture was incubated at 65oC for 5 minutes. The microtubes were quickly cooled on ice. RT 
buffer, dithiothreitol (DTT)(0.002M), RT-MLV (10 U) and RNase inhibitor (2 U) were added to 
the mixture according to manufacturer’s instructionsj. This final mixture was incubated at 37oC 
for 55 minutes and at 70oC for 15 minutes, successively. The PCR mixture containing double 
distilled water, 1.5 µL cDNA, PCR buffer, 2.5 mM MgSO4 , 0.5 mM dNTP, 0.25 U Taq 
polymerase and, sense and antisense primers of ET-A or ET-B or β-actin was prepared according 
to manufacturer’s instructionsj. PCR reactions were performed in master cycler gradient PCR 
machinek at 40 cycles. The following conditions were used for PCR: denaturation at 94o C for 15 
seconds, annealing at 55o C for 15 seconds for ET-A and 60o C for 15 seconds for ET-B and β-
actin, respectively, and extension at 72o C for 30 seconds. In each experimental run, negative 
controls (without reverse transcriptase) were used. To each microtube containing PCR product, 2 
µL of loading buffer were added.  The products and the standard (2 µL) were loaded into 1.4% 
PCR gel placed in an electrophoresis tank containing Tris-Acetate-EDTA(TAE) buffer. Then 
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electrophoresis was conducted at 80 volts for 40 minutes. Bands were detected by using Bio 
Rad’s Versa Doc Imaging system.l 
4.2.10 Real-Time Polymerase Chain Reaction (PCR) – For reverse transcription, 1.5 µg of 
total RNA was used. To each sample, oligo dT (0.002µM) and dNTPs (0.5µM) were added. The 
mixture was incubated at 65oC for 5 minutes. The microtubes were quickly cooled on ice. RT 
buffer, dithiothreitol (DTT) (0.002M), RT-MLV (10 U) and RNase inhibitor (2 U) were added to 
the mixture according to manufacturer’s instructionsj. This final mixture was incubated at 37oC 
for 55 minutes and at 70oC for 15 minutes successively. The PCR mixture containing double 
distilled water, 1.5 µL cDNA, PCR buffer, 2.5 mM MgSO4 , 0.5 mM dNTP, 0.25 U Taq 
polymerase and, sense and antisense primers of ET-A or ET-B was prepared according to 
manufacturer’s instructionsj. Real-time PCR was conducted by using Biorad’s iTaq SYBR Green 
Supermix with Rox. Horse Glyseraldehyde-3-phosphate dehydrogenase (GAPDH) was used as 
house-keeping gene. Following nucleic acid sequences of primers of equine GAPDH were used: 
Forward primer: 5’-ccagaacatcatccctgctt-3’ and reverse primer: 3’-cgtatttggcagctttctcc-5’. All the 
real-time experiments were performed in Applied Bioscience 7900 Sequence Detection System. 
The comparative CT or ∆∆CT method was used for data analysis.  
4.2.11 Western Blotting – Five independent replications per each horse (n=8) were performed 
for Western blot studies. We conducted Western blot studies as supportive studies for both RT-
PCR and immunohistochemistry studies. Hence we used small sample size i.e. four horses in 
each group. For the Western blotting, lung protein extracts were prepared by homogenizing the 
thawed equine and rat lung samples in Camiolo buffer [0.075M Potassium acetate, 0.3M NaCl, 
0.1M L-arginine basic salt, 0.01M EDTA-HCl and 0.25% Triton X-100] containing a protease 
inhibitor cocktail. Extracts were centrifuged at 10,000 g for 15 min at 4oC. Supernatant fractions 
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were assayed for protein concentration by using Bradford reagent l and were used for Western 
blot analysis. Western blot analysis was performed as previously described (McMullan et al. 
2001 and Black et al. 1997). Briefly, protein extracts (40 µg) were separated on 10% denaturing 
polyacrylamide gels for ET-A and ET-B receptors. Pre-stained protein markers were also run in 
the gel. All gels were electrophoretically transferred to polyvinylidene fluoride membranes. 
Efficiency of protein transfer was evaluated by using Ponceau S staining. The membranes were 
blocked with 5% nonfat dry milk in Tris-buffered saline containing 0.1% Tween. After blocking, 
the membranes were incubated for one hour at room temperature with 1:500 dilution of either 
ET-A or ET-B antisera, washed 3 times (for 10 minutes each wash) with Tris-buffered saline 
containing 0.1% Tween, and then incubated with donkey anti-sheep IgG-horseradish peroxidase 
conjugate.m The membranes were then washed 3 times (for 10 minutes each wash) with Tris-
buffered saline containing 0.1% Tween and protein bands were visualized by enhanced 
chemiluminescencen according to manufacturer’s instruction using Bio-Max MR film.o Protein 
band sizes were determined by using Quantity One image analysis software.l The Western blot 
membranes were stripped in the stripping buffer (62.5 mM Tris at pH of 6.7, 2% SDS and 100 
mM β mercaptoethanol) for 30 minutes at 60oC with occasional agitation. Then the membranes 
were washed twice in the washing buffer for 10 minutes each. These membranes were used for 
detecting β actin bands by using goat-polyclonal antibodies. Bands were detected using Bio 
Rad’s Versa Doc Imaging system.l 
4.2.12 Detection and Quantification of Bands – Western blot and RT-PCR product bands were 
analyzed and the average intensity of the bands was determined by using Bio Rad’s Quantity 
One Quantitation software.l The data were collected in terms of average intensity of bands of 
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ET-A or ET-B receptors per average intensity of bands of β−actin, and imported to 
MICROSOFT EXCEL.p 
4.2.13 Preparation of Slides for Immunohistochemistry – Five independent replications were 
performed (n=14) for immunohistochemical studies. Tissue sections measuring 4 µm in 
thickness were cut from each paraffin block and mounted on clean sialinized slides. From each 
paraffin block, three slides were prepared. Two of three slides were used for detecting the ET 
receptors (ET-A and ET-B) and the other slide was used as a negative control (without primary 
antibody).  These tissue sections were deparaffinized with xylene and subsequently rehydrated 
with graded concentrations of ethyl alcohol (100%, 90% and 70%), respectively. Then, all slides 
were subjected to immunohistochemistry (Furuya et al. 2005 and Naylor et al. 1992). 
4.2.14 Immunohistochemistry – The automated Dako Autostainerq was used to perform the 
immunohistochemistry studies. Optimization of the antibody showed that the staining was best 
when no antigen retrieval method was used. Except when noted, all rinsing steps were conducted 
with TRIS-Buffered Saline (TBS) at pH 7.6 containing 0.05% Tween-20. After rinsing the slides 
with TBS, the endogenous peroxidase activity of the tissues was blocked by applying 3% H2O2 
for 10 min. Sections were then rinsed and endogenous avidin and biotin were blocked for 10 
minutes each by using avidin/biotin blocking agent.r After rinsing all of the slides, endogenous 
protein was blocked for 30 minutes at room temperature by adding normal rabbit serum.s 
Manufacturer’s guidelines were followed to prepare the blocking serum. After blowing off the 
excess blocking serum, the tissue sections on the slides were incubated with either sheep anti ET-
A receptor polyclonal primary antibodiese or sheep anti ET-B polyclonal primary antibodiese at 
1:200 dilutions each, for 30 minutes at room temperature. In the negative controls, the primary 
antibody was replaced by sheep gamma globulint at 1:1,000 dilutions. Antibodies and sheep 
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gamma globulins were diluted in DAKO antibody diluentq. After rinsing all of the slides, 
biotinylated rabbit anti-sheep IgG secondary antibodiesr were applied to the sections for 30 
minutes. After rinsing the slides, Vectastain elite ABC immunoperoxidase systems was applied 
to the tissue sections. Then, all of the tissue sections were washed with TBS. Sites of 
immunostaining were visualized by developing sections in Nova red s (substrate for peroxidase), 
which was applied to the sections for 8 minutes. After washing with TBS followed by deionized 
water, the slides were counterstained with Mayer’s hematoxylin for 5 minutes. The slides were 
then thoroughly washed with TBS and deionized water, respectively. The sections were 
dehydrated through graded concentrations of ethyl alcohol and cleared with xylene. Finally, the 
sections were mounted with Permount and glass cover slips and allowed to dry.  
4.2.15 Evaluation of Immunohistochemistry Slides – The immunohistochemistry slides were 
independently evaluated by two authors (Polikepahad S and Venugopal CS) for staining 
intensity. The staining intensities of ET-A and ET-B receptors were scored after comparing them 
to that of negative control, the score of which was considered zero. The results were interpreted 
as absence of staining (0), weak staining (1+), moderate staining (2+) and strong staining (3+).  
4.2.16 Evaluation of Slides for Pathological Changes – Five slides, one from each of the 6 
horses in each group were evaluated for the presence of pathological changes in the bronchioles, 
blood vessels and alveoli. Each slide was evaluated independently by two authors (Polikepahad S 
and Venugopal CS) and scores were assigned based upon the intensity of the pathological change 
(Naylor et al. 1992). The pathological changes evaluated included Goblet cell metaplasia, 
epithelial hyperplasia, mucus plugs in the bronchioles, neutrophils in the bronchiolar lumen, 
peribronchial eosinophils, alveolar macrophages, peribronchiolar inflammation, perivascular 
inflammation and alveolar inflammation. The results were interpreted as 0 (absence of the 
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pathological change), 1+ (weak presence), 2+ (moderate presence) and 3+ (strong presence). The 
results were reported as median and range values.  
4.2.17 Statistical Analysis – Graph pad Prism ver.4.0u was used for performing all statistical 
analyses. The CS and ∆Ppl data was analyzed and comparison between clinically healthy and 
SPAOPD-affected horses using the Mann-Whitney test. The immunohistochemistry staining 
scores and histopathology scores were evaluated and compared between clinically healthy and 
SPAOPD-affected horses using the Kruskal-Wallis test. Selected pair-wise comparisons were 
made using Dunn's multiple comparison tests. Data pertaining to band intensities for the Western 
blotting and RT-PCR, and real-time PCR were statistically analyzed using two-way ANOVA. 
Pair-wise comparisons were made by employing post-hoc Bonferroni tests. All statistical 
analyses were performed at the level of significance of p < 0.05. 
4.3 Results  
4.3.1 Clinical Evaluation – The mean values of heart rate, respiratory rate and rectal 
temperature for clinically healthy and SPAOPD-affected horses are given in Table 4.1.  
Table 4.1– Signalment, clinical variables, clinical score, and ∆Ppl for SPAOPD-affected horses 
and healthy horses. * Clinical score assigned on a scale of 0 to 8. a,b Values with different 
superscript letters differ significantly (P ≤ 0.05). y = years, bpm = beats per minute, rpm = 
respirations per minute, CS = clinical score and ∆Ppl = transpleural pressure. 
 
        SPAOPD-affected horses Healthy horses 
Variable Median Range Median Range 
Age (y) 16.5 10-20 15.8 10-20 
Temp (oF) 100.2 98.6-102.0 100.4 100.0-102.0 
HR (bpm) 43 31-68 39 34-63 
RR (rpm) 23 18-37 22 17-24 
CS* 5.50 5.0-7.0 1.5 1.0-3.5 




             All horses were in relatively good body condition and had a normal appetite and 
demeanor. All SPAOPD-affected horses had respiratory wheezes on auscultation, nostril flaring, 
increased abdominal lift and cough. Few SPAOPD-affected horses showed a marked ‘heave’ line 
extending along the abdominal wall. The CS (median 5.5; range, 5.0 to 7.0) of SPAOPD-affected 
horses was significantly greater than that of clinically healthy horses (median 1.5; range, 1.0 to 
3.5; Table 1).  Similarly, the ∆Ppl of SPAOPD-affected horses (median 25.0 cm of H2O; range 
20 to 32) was significantly greater than that of clinically healthy horses (median 7.0 cm of H2O; 
range, 4.0 to 9.0).   
4.3.2 Gross Post-Mortem Evaluation of Lungs – The lungs of all SPAOPD-affected horses 
were over-inflated and orange-pink in color. In these horses, after the thoracic cavity was 
opened, the lungs did not collapse. A tough texture was observed in some regions of the lungs. 
Non-uniformly distributed pale fibrotic patches were observed on the surface of the lungs of 
many affected horses. In addition, the surface of the lungs of some affected horses had 
indentions or impressions caused by the pressure from the ribs. Mucus plugs were frequently 
observed in the bronchi; however, this observation was not uniform throughout the lung fields. 
           Healthy horses had lungs which were of normal size, texture and pale pink in color. 
Neither fibrotic patches nor rib impressions were noticed on the lung surface. The lungs 
collapsed immediately and completely after opening the thoracic cavity. Bronchial mucus plugs 
were noticed on only a few occasions. 
4.3.3 Microscopic Evaluation for Histological Changes – The microscopic findings are given 





Table 4.2 – Different pathological changes were evaluated and scored from 0 to 3, based on the 
degree of the change. The evaluated scores were statistically compared between clinically 
healthy and SPAOPD-affected horses. 
 
 
 Healthy (n=6; 





difference   (P 
≤ 0.05) 
Goblet cell metaplasia 0.00 ± 0.00 1.33 ± 0.33    Yes 
Epithelial hyperplasia 0.20 ± 0.20 1.87 ± 0.27    Yes 
Mucus plugs in the bronchioles 0.00 ± 0.00 1.94 ± 0.30    Yes 
Neutrophils in the bronchiolar lumen 0.06 ± 0.06 1.94 ± 0.31    Yes 
Peribronchial eosinophils  0.13 ± 0.09 0.80 ± 0.26     No  
Alveolar macrophages 0.06 ± 0.06 0.60 ± 0.17     No 
Peribronchiolar inflammation 0.13 ± 0.09 2.47 ± 0.13    Yes 
Perivascular inflammation 0.13 ± 0.13 0.80 ± 0.14     No 
 136
 
Figure 4.1 – Section of SPAOPD-affected lung. Note the presence of mucus plugs in the lumen 
of bronchioles and peribronchial inflammation. 
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Figure 4.2 – Section of SPAOPD affected lung. Note the presence of excessive neutrophils in 










          




Figure 4.3 – Section of SPAOPD affected lung. Note the bronchiolar epithelial cell hyperplasia 
in the section of SPAOPD-affected lung. 
 
            The most consistent finding in the lungs of SPAOPD-affected horses was the presence of 
mucus plugs in the bronchioles (Figure 4.1).  Other consistent and significant findings in the 
SPAOPD-lungs were the presence of goblet cell metaplasia, bronchiolar epithelial hyperplasia, 
infiltration of neutrophils into the bronchiolar lumen and peribronchial inflammation (Figure 4.2 
and Figure 4.3). 
            In addition, weak to moderate infiltration of eosinophils was noticed in 3 of the 6 
SPAOPD-affected horses. Although not statistically different from clinically healthy horses, few 
alveolar macrophages and mild perivascular and alveolar inflammation were noticed in all 
SPAOPD-affected horses. None of the SPAOPD-affected lungs had true pulmonary emphysema. 
  500 µm 
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In healthy horses, none of the aforementioned changes were observed except for very mild 
epithelial hyperplasia and peribronchial and alveolar inflammation in 2 of the 6 horses. 
4.3.4 Antibody and Primer Specificity – The protein band sizes and RT-PCR product sizes of 
ET-A and ET-B receptors of rat lungs matched with those of equine lung samples. For the 
immunohistochemistry, rat lung sections showed intense immunostaining for both receptors and 
no staining was observed in negative controls. Similarly, the horse lung sections showed 
immunostaining for both receptors and no staining was detected in the negative control sections. 
4.3.5 Findings of RT-PCR Studies – There was no difference in the mean intensity of ET-A 
receptor bands between healthy and SPAOPD-affected horses, whereas the mean intensity of 
ET-B receptor bands was significantly greater (~ 4-fold) in SPAOPD-affected horses compared 
with healthy horses (Figure 4.4 and Figure 4.5). In healthy horses, there was no difference 
between the mean intensities of ET-A and ET-B receptors; however, in SPAOPD-affected 
horses, the mean intensity of ET-B receptors was significantly greater (~ 4-fold) than that of ET-
A receptors.  
4.3.6 Findings of Western Blotting Studies – The mean band intensities of ET-A and ET-B 
receptors were significantly greater (~ 1.6-fold and ~ 2-fold, respectively) in lungs of SPAOPD-
affected horses compared with values from healthy horses, respectively (Figure 4.6 and Figure 
4.7). In healthy horses, there was no difference between the mean intensities of ET-A and ET-B 
receptors; however, in SPAOPD-affected horses, the mean intensity of ET-B receptors was 







Figure 4.4 – RT-PCR bands of ET-A and ET-B receptors and β-actin in healthy and SPAOPD-
affected horses. The mean sizes of the RT-PCR bands for β-actin, and ET-A and ET-B receptors 
were 160, 190 and 220 base pairs, respectively. 
 
Figure 4.5 – Mean ± SEM for the mean intensity of the ET-A and ET-B receptor bands per 
mean intensity of β-actin bands in healthy (n=7) and SPAOPD-affected (n=7) horses. The * 
indicates a statistically significant difference (P < 0.05) in the mean intensities of ET-B receptors 
between healthy and SPAOPD-affected horses. The † indicates a statistically significant 





Figure 4.6 – Western blot bands of ET-A and ET-B receptors and β-actin in healthy and 
SPAOPD-affected horses. The mean sizes of western blot bands for β-actin and ET-receptors 




Figure 4.7 – Mean ± SEM for the intensity of the ET-A or ET-B receptor bands per mean 
intensity of β-actin bands in clinically healthy (n=4) and SPAOPD-affected (n=4) horses. The * 
indicates statistically significant difference (P < 0.05) in the intensities of ET-B receptors 
between healthy and SPAOPD-affected horses. The † indicate a statistically significant 
difference (P < 0.05) between the intensities of ET-A and ET-B receptors in SPAOPD-affected 
horses. The ‡ indicates statistically significant difference (P < 0.05) in the intensities of ET-B 




Figure 4.8 – Immunostaining of equine alveolar tissue from an SPAOPD-affected horse (20X 
maginification) where the primary antibody was replaced with sheep gamma globulin as a 
negative control. 
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Figure 4.9 – Immunostaining of equine alveolar tissue from the same tissue sample as used for 
the negative control,but in which anti ET-B receptor antibody was applied. 
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Figure 4.10 – Immunostaining of ET-B receptors can be observed in the luminal side of 
bronchial epithelium of the lung from an SPAOPD-affected horse and epithelial hyperplasia can 
also be clearly noticed.   
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Figure 4.11 – Mean (± SEM) of ET-A and ET-B receptor immunostaining in the lungs of 
healthy (n=7) and SPAOPD-affected horses (n=7). The * indicates statistically significant 
difference (P < 0.05) in the intensities of ET-B receptors between healthy and SPAOPD-affected 
horses. The † indicate a statistically significant difference (P < 0.05) between the intensities of 
ET-A and ET-B receptors in SPAOPD-affected horses. The ‡ indicates statistically significant 
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Figure 4.12 – Mean (± SEM) of relative ET-A and ET-B receptor gene expression in the lungs 
of healthy (n=7) and SPAOPD-affected horses (n=7). The * indicates statistically significant 
difference (P < 0.05) in the relative gene expression of ET-B receptors between healthy and 
SPAOPD-affected horses. The † indicates a statistically significant difference (P < 0.05) in the 
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4.3.7 Findings of Immunohistochemistry Studies – The findings of immunohistochemistry 
studies were similar to those of Western blotting. The mean score for ET-A and ET-B receptor 
immunostaining was significantly greater (~ 1.7-fold and ~ 2.1-fold, respectively) in lungs of 
SPAOPD-affected horses, compared with values in healthy horses (Figures 4.8, 4.9, 4.10 and 
4.11). In healthy horses, there was no difference between the mean scores for ET-A and ET-B 
receptor immunostaining; however, in SPAOPD-affected horses, the mean score of ET-B 
receptor immunostaining was significantly greater (~ 1.6-fold) than that of ET-A receptors. 
4.3.8 Findings of Real-Time PCR Studies – Findings of real-time PCR studies have agreed 
with the other studies. The relative gene expression of ET-B receptors was ~ 50 times greater in 
SPAOPD-affected horses when compared to clinically healthy horses (Figure 4.12). The relative 
gene expression of ET-A receptors was ~ 10 times greater in SPAOPD-affected horses when 
compared to clinically healthy horses. 
4.4 Discussion 
           The findings of this study are interesting and thought provoking. First, by using RT-PCR, 
we demonstrated that the mRNA of ET-A and ET-B receptors is expressed in the lungs of 
healthy and SPAOPD-affected horses, and the expression of ET-B receptor mRNA is 
significantly greater in SPAOPD-affected horses when compared to healthy horses. However, no 
change was observed in the ET-A receptor mRNA expression between the two groups of horses. 
Second, by employing Western blotting and immunohistochemistry, we showed that ET-A and 
ET-B receptors are expressed in equine lungs and the expression of both of these receptors is 
significantly greater in the lungs of SAPOPD-affected horses than that of clinically healthy 
horses. Third, all three techniques revealed that there is no difference between the expression of 
ET-A and ET-B receptors in the lungs of healthy horses. Finally, all three techniques revealed 
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that ET-B receptors are significantly over-expressed in the lungs of SPAOPD-affected horses, 
compared with healthy horses and compared with ET-A receptors in the same horses. 
 Since the present study demonstrated significant differences in the expression of ET-
receptors between the two groups of horses, we wanted to confirm that the grouping of horses 
was properly performed. All SPAOPD-affected horses that were used in this study were kept in 
the pasture until they began showing clinical exacerbations. Clinical evaluation was conducted 
immediately after the horses started showing the symptoms of SPAOPD. During the clinical 
evaluation, all affected horses showed the characteristic signs of obstructive pulmonary diseases 
such as cough, exaggerated expiratory effort, respiratory wheezes on auscultation, abdominal lift 
and flared nostrils (Seahorn and Beadle 1993). The findings in our gross post-mortem evaluation 
and histopathologic evaluation in SPAOPD-affected horses are in agreement with the previous 
reports (Costa et al. 2000). The hyper-inflation of the lungs that was noticed during post-mortem 
evaluation of SPAOPD-affected horses is believed to be due to the trapping of air in post-
obstructive areas of the lung. This hyper-inflation is the cause of the rib impressions that were 
observed on the surface of the lungs of some SPAOPD-affected horses. Because of the entrapped 
air, SPAOPD-affected lungs did not collapse when the thoracic cavity was opened. 
Histologically, the consistent findings in SPAOPD-affected horses were the presence of 
neutrophil-filled mucus plugs and goblet cell metaplasia in the bronchioles, and epithelial 
hyperplasia of bronchi (Costa et al. 2000). All of these changes contribute substantially to 
obstruction of the airways in this disease.  
             Previously, Benamou et al suggested involvement of ET-1 in the pathogenesis of equine 
RAO by demonstrating the presence of elevated levels of ET-1 in the pulmonary circulation and 
BALF of RAO-affected horses (Benamou et al. 1998). This concept of ET-1 involvement in 
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equine allergic pulmonary disease is complemented by the findings of the present study, which 
showed that the expression of ET-receptors, especially that of ET-B receptors, is significantly 
increased in the lungs of SPAOPD-affected horses. Compelling evidence exists for the 
involvement of ET-1 in the pathogenesis of human allergic airway diseases (Michael and 
Markewitz 1996). For example, in human asthmatic airways, ET-1 has been shown to stimulate 
mucus secretion, airway edema through microvascular leakage, smooth muscle mitogenesis and 
bronchial hyperresponsiveness (Michael and Markewitz 1996). Similarly, in human COPD, ET-1 
has been implicated in the activation of neutrophils, and alveolar macrophages and pulmonary 
hypertension secondary to COPD (Ronald et al. 2001). As far as the ET-receptors are concerned, 
there is paucity of literature regarding alteration of their expression in airway allergic diseases.  
Moller et al. demonstrated that the ratio of ET-A and ET-B receptor mRNA is altered in the 
bronchial biopsies from human patients with asthma and chronic airway obstruction. By 
employing RT-PCR techniques, they showed that the bronchial biopsies of these patients express 
significantly greater ET-B receptor mRNA expression compared with ET-A receptor mRNA 
(Moller et al. 1999). In contrast, by employing quantitative autoradiography studies, Knott et al. 
showed that asthma is not associated with any significant alteration in the densities of ET-A and 
ET-B receptors in the peripheral human lung (Knott et al. 1995). In these studies, they also 
demonstrated that in both asthmatic and non-asthmatic individuals, approximately 30% of the 
ET-1 binding was to ET-A receptors whereas approximately 70% was to ET-B receptors (Knott 
et al. 1995). In the current study, all three techniques showed that ET-B receptor expression is 
significantly greater in the lungs of SPAOPD-affected horses compared to healthy horses; 
however, although Western blotting and immunohistochemical studies demonstrated the over-
expression of ET-A receptors in SPAOPD-affected horses, RT-PCR studies showed no 
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difference in the ET-A mRNA expression between the two groups. The reason for this 
discrepancy is not clear at this point. Perhaps the post-transcriptional regulatory mechanisms 
might have significant influence during the synthesis of ET-A receptors. Further studies are 
required to establish the exact cause of this finding. 
             In the current study, we also demonstrated that the significant over-expression of ET-B 
receptors in the lungs of SPAOPD-affected horses is much greater than the over-expression of 
ET-A receptors. These findings suggest that ET-B receptors might play a greater role than ET-A 
receptors in the pathogenesis of SPAOPD. However, considering the fact that the role of ET-1 is 
not yet confirmed in the pathogenesis of SPAOPD, it is premature to draw this conclusion. 
Nevertheless, our findings in this study could form a strong basis for future functional studies 
regarding the involvement of ET-1 in the pathogenesis of SPAOPD. 
            In conclusion, the present study provides molecular evidence for the presence of ET-
receptors in the lungs of healthy and SPAOPD-affected horses. In addition, we also 
demonstrated for the first time that both types of ET-receptors, particularly ET-B receptors, are 
over-expressed in the lungs of SPAOPD-affected horses. We believe that these findings could 
form a basis for future clinical studies involving use of ET-receptor antagonists in alleviating the 
symptoms of this disease.  
4.5 Footnotes 
 
a  Polikepahad S, Moore RM, Krishnakumar S et al. Pharmacological characterization of 
endothelin receptor responses of bronchi in clinically healthy horses and those affected with 
summer pasture associated obstructive pulmonary disease. Abstract # 653.7: FASEB Journal 
2003 San Diego, CA. 
 
b Esophageal balloon, AE Medical, Farmingdale, NJ. 
c Model 7D polygraph, Grass Medical Instrument Division of Astro-Med, Inc.WestWarwick, RI. 
d Sodium pentobarbital (Beuthanasia), Scherring-Plough Animal Health Corp, Kenilworth, NJ. 
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e Sheep Antibody to Endothelin A Receptor and  Sheep Antibody to Endothelin B Receptor, 
BIODESIGN International, Saco, Maine. 
 
f   RNase Zap® RNase decontamination solution, Ambion®, Inc., Austin, TX. 
g  TRI Reagent® Molecular Research Center, Inc., Cincinnati, OH. 
 h Ultra-Turrax T8®, IKA® Works, Inc., Wilmington, NC 
 i  NanoDrop® ND-1000 Spectrophotometer, NanoDrop Technologies, Wilmington,   DE  
j  M-MLV Reverse Transcriptase and Platinum® Pfx DNA Polymerase Invitrogen Corporation, 
Carlsbad, CA. 
 
k Eppendorf ® Mastercycler ® gradient, Eppendorf, Westbury, NY. 
l VersaDoc imaging system  Model 1000, Quick Start Bradford Protein Assay Kit 1 and Quantity 
one 1-D image analysis software, Bio-Rad Laboratories,  Hercules, CA. 
 
m  Donkey anti-sheep IgG-HRP, Santa-Cruz Biotechnology, Santa Cruz, CA. 
n  Western lightening chemiluminscence reagent, PerkinElmer Life Sciences, Boston, MA. 
o  BioMax MR film, Eastman Kodak Company, Rochester, NY. 
p Microsoft Corporation, Redmond, WA. 
q  Dako Autostainer Universal Staining system, DakoCytomation California Inc, Carpinteria, CA. 
r Avidin/Biotin Blocking Kit, Vector laboratories, Inc., Burlingame, CA. 
 
s  Vectastain Elite ABC Kit (Sheep IgG) and Vector NovaRED Substrate Kit for Peroxidase,   
Vector laboratories, Inc., Burlingame, CA. 
 
t   Jackson ImmunoResearch laboratories, Inc., West Grove, PA. 
u Graphpad Prism Verion 4.0, GraphPad Software, Inc., San Diego, CA. 
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